[
{
"nct": "NCT00005947",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sipuleucel-T, autologous cellular immunotherapy for prostate cancer."
},
{
"nct": "NCT00065442",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sipuleucel-T, autologous cellular immunotherapy for prostate cancer."
},
{
"nct": "NCT00090220",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups (Day 1 to about Month 48); left out EG002 (open-label qHPV in EXT1) and EG003 (long-term follow-up of vaccinated participants)."
},
{
"nct": "NCT00090233",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq (live human-bovine reassortant) vs placebo matching RotaTeq; placebo composition not given. SAE and other-AE tables use the same two groups."
},
{
"nct": "NCT00090285",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups; left out EG002 (open-label qHPV in EXT1) and EG003 (LTFU, mixes both base-study arms)."
},
{
"nct": "NCT00092443",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo described only as matching RotaTeq."
},
{
"nct": "NCT00092456",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three RotaTeq lots; placebo described only as matching RotaTeq."
},
{
"nct": "NCT00092521",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Quadrivalent HPV (EG000) and monovalent HPV 16 vaccine (EG001) against one placebo, base study; left out EG003 (extension, open-label qHPV for those not fully vaccinated, mixes arms)."
},
{
"nct": "NCT00092534",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Base Study groups 1 (qHPV, Gardasil, aluminium adjuvant) and 2 (placebo). Left out EG002 (Base Study EXT, placebo recipients crossed over to qHPV) and EG003/EG004 (LTFU, after crossover). 'Matching placebo' composition not stated in the record."
},
{
"nct": "NCT00092547",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups (Day 1 to Month 30); left out EG002 and EG003 (extension Month 30 onward, placebo recipients then given qHPV)."
},
{
"nct": "NCT00094653",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "gp100 melanoma peptide vaccine with or without ipilimumab."
},
{
"nct": "NCT00095576",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MRKAd5 HIV-1 gag/pol/nef (Ad5 vector) preventive vaccine in HIV-uninfected high-risk adults."
},
{
"nct": "NCT00112112",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "FluMist in immunocompromised children with cancer; placebo was allantoic fluid with sucrose-phosphate-glutamate buffer (excipients, no antigen)."
},
{
"nct": "NCT00119067",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"anthrax"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled all AVA route/schedule groups against saline placebo; AVA is adsorbed protective-antigen filtrate (aluminium hydroxide)."
},
{
"nct": "NCT00127803",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three toxoid doses; placebo called vaccine diluent, record gives no adjuvant in it."
},
{
"nct": "NCT00128219",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Td vaccine (active control)."
},
{
"nct": "NCT00133575",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "Dryvax smallpox vaccine at about day 180"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled MVA doses and routes against saline; all participants got Dryvax at about day 180, inside the AE window."
},
{
"nct": "NCT00157950",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo described only as matching Gardasil."
},
{
"nct": "NCT00158756",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Tritanrix-HepB (DTPw-HBV)"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Zilbrix (DTPw-HBV Kft)"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rotarix vs Rotarix placebo, one comparison per co-administered DTPw-HBV product; left out EG004 (Triple Antigen + Engerix-B, no Rotarix or placebo). Open-label for the DTPw-HBV part."
},
{
"nct": "NCT00166517",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT00197054",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Rabipur rabies vaccine (active control)."
},
{
"nct": "NCT00199901",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "NY-ESO-1 melanoma vaccine vs ISCOMATRIX adjuvant alone."
},
{
"nct": "NCT00201448",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control labelled placebo was hepatitis A vaccine (active control)."
},
{
"nct": "NCT00212888",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccination (Remune, ALVAC) in HIV-infected patients on ART before treatment interruption."
},
{
"nct": "NCT00214461",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three toxoid doses; placebo called vaccine diluent buffer, record gives no adjuvant in it."
},
{
"nct": "NCT00223080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV (canarypox vector) prime with AIDSVAX B/E gp120 in aluminium hydroxide. The placebo is the ALVAC carrier without virus plus the AIDSVAX placebo, which the record lists as aluminium hydroxide adjuvant.",
"third_reader_reason": "The coders differed only on what the placebo held. The record lists the placebo's two parts as 'ALVAC carrier lyophilized product without virus' and 'Aluminum hydroxide adjuvant', so the AIDSVAX placebo is the adjuvant alone and the content is adjuvant, as coder 1 read it."
},
{
"nct": "NCT00224484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hepatitis_a",
"herpes_simplex"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gD2-AS04 (EG000) and Havrix, the active control (EG001), each against saline (EG002) over the active period, months 0 to 12. EG003 repeats the gD2-AS04 participants over the extended follow-up and EG004 pools Havrix and saline recipients, so both are left out.",
"third_reader_reason": "The coders differed on the Havrix arm: coder 1 took it as a second vaccine group, coder 2 left it out as an active control. Note 9 makes a licensed vaccine given as an active control a vaccine group when it differs from the placebo arm only in that vaccine, which holds here (same three-dose schedule), so Havrix is in and hepatitis A is a target."
},
{
"nct": "NCT00231179",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Home-visiting behavioral intervention, no vaccine."
},
{
"nct": "NCT00231816",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms got Zostavax and influenza vaccine; only timing differs."
},
{
"nct": "NCT00239577",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three formulations against placebo; 17b and 19 groups also got a booster without a placebo counterpart, covered only by the SAE window."
},
{
"nct": "NCT00241644",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine EPI vaccines"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the 2-dose and 3-dose Rotarix groups; left out EG002, which pools the same participants again."
},
{
"nct": "NCT00244374",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_a",
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms got hepatitis A/B vaccine; trial compares delivery and adherence support."
},
{
"nct": "NCT00258154",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Infanrix hexa"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT00263666",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Tritanrix-HepB/Hib and oral polio vaccine"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HIV-infected infants."
},
{
"nct": "NCT00270205",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "DermaVir therapeutic HIV DNA vaccine in people with HIV on HAART."
},
{
"nct": "NCT00273910",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "gp100 melanoma peptide vaccine with adjuvants; no placebo either."
},
{
"nct": "NCT00275262",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Leuprolide vs placebo for immune recovery after stem cell transplant; KLH immunization given to all."
},
{
"nct": "NCT00287469",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hepatitis_e"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo was PBS containing alum."
},
{
"nct": "NCT00289341",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Autologous dendritic-cell prostate cancer vaccine."
},
{
"nct": "NCT00290355",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MAGE-A3 cancer immunotherapeutic in resected NSCLC."
},
{
"nct": "NCT00294047",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04) vs aluminium hydroxide control."
},
{
"nct": "NCT00303069",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V710 is recombinant S. aureus IsdB protein; three single-dose levels pooled against saline. The record doesn't say whether this formulation held aluminium adjuvant, and V710 was made both with and without it.",
"third_reader_reason": "The coders differed on the adjuvant: coder 1 gave aluminium from product knowledge, coder 2 unknown. The record states no adjuvant and V710 was studied both with and without Merck's aluminium adjuvant, so I am not confident which this trial used, and note 1 then calls for unknown."
},
{
"nct": "NCT00308061",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Imovax rabies vaccine (active control)."
},
{
"nct": "NCT00310856",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm got MenACWY-CRM; open-label schedule comparison."
},
{
"nct": "NCT00313911",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b",
"other",
"polio",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Tritanrix-HepB/Hib plus OPV (active control). Other target: Haemophilus influenzae type b."
},
{
"nct": "NCT00314132",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChimeriVax-JE vs 0.9% saline."
},
{
"nct": "NCT00314145",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was JE-VAX (active control); saline only filled schedule gaps."
},
{
"nct": "NCT00316303",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_a",
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Twinrix within a behavioral package vs enhanced usual care, no placebo."
},
{
"nct": "NCT00316524",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Randomized vaccinia-naive groups: two doses and one dose plus placebo against two Tris-buffer placebos; left out EG003 (vaccinia-experienced, not randomized, no placebo)."
},
{
"nct": "NCT00319098",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Fluarix seasonal vaccine plus placebo (active control)."
},
{
"nct": "NCT00319592",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was JE-VAX (active control); saline only filled schedule gaps."
},
{
"nct": "NCT00322231",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover; AE groups pool both periods by product received, so each participant is in both groups and no first-period groups are reported."
},
{
"nct": "NCT00325819",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Acetaminophen vs placebo after routine vaccines every child received."
},
{
"nct": "NCT00329745",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Year-3 extension of the primary study, groups by original randomization; only AEs leading to withdrawal were collected."
},
{
"nct": "NCT00329901",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "Tdap vaccine"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenACWY-CRM vs saline, both with Tdap; left out EG002 (MenACWY + saline), since EG000 can serve only one comparison and MenACWY is the trial's focus."
},
{
"nct": "NCT00339040",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Arm B got placebo at weeks 0, 8 and 24 and then the vaccine from week 96; the only groups run from the first dose to study completion, past that point. HIV-infected children.",
"third_reader_reason": "Coder 1 excluded the trial because the placebo arm got the vaccine at week 96 inside its only group; coder 2 kept it with a caveat. Note 7 settles it: when the only groups run past the point where placebo recipients were vaccinated, the trial is ineligible as groups_not_randomized_arms."
},
{
"nct": "NCT00344032",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04); placebo composition not given."
},
{
"nct": "NCT00345878",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04); placebo composition not given."
},
{
"nct": "NCT00346398",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral allergen immunoprophylaxis for allergy and asthma."
},
{
"nct": "NCT00350337",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three formulations against EMEM/stabilizer placebo; post-transfection F17 and F19 groups also got a booster without a placebo counterpart, inside the groups."
},
{
"nct": "NCT00362648",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the all-randomized groups (SAEs 14 days); left out EG002-EG003 (cross-treated, mix arms) and EG004-EG005 (Kenya subset of the same participants, 42-day follow-up)."
},
{
"nct": "NCT00365378",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent HPV 16 VLP (Merck, aluminium adjuvant); left out EG002 (extension, mixes arms)."
},
{
"nct": "NCT00365716",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003",
"EG004"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three qHPV formulations against two aluminium-adjuvant placebos; left out EG005 (extensions, mixes arms)."
},
{
"nct": "NCT00370682",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two formulations of WRAIR live attenuated tetravalent dengue vaccine pooled; placebo is sterile buffer."
},
{
"nct": "NCT00378560",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil (aluminium adjuvant); placebo composition not given."
},
{
"nct": "NCT00381615",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label; rMenB +/- OMV groups compared with routine-vaccines-only groups (who got rMenB later), no placebo."
},
{
"nct": "NCT00382408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral tablets of live adenovirus types 4 and 7; target other = respiratory illness from adenovirus types 4 and 7. Placebo tablets matched the vaccine, composition not given.",
"third_reader_reason": "The coders differed on the platform: live_attenuated (coder 1) or other (coder 2), since the virus is live but not attenuated. Note 2 names oral adenovirus types 4 and 7 as live_attenuated, a live organism given as the vaccine against itself."
},
{
"nct": "NCT00396630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rotarix vs placebo, 2 doses; both groups could get a complimentary Rotarix dose at week 13 (study end); AE time frame not stated, took the arm groups as reported."
},
{
"nct": "NCT00397891",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Bapineuzumab, a monoclonal antibody for Alzheimer's disease."
},
{
"nct": "NCT00397943",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got the adjuvant system alone (which one, AS01B or AS02A, not stated). Vaccine groups: M72/AS01B, M72/AS02A, Mtb72F/AS02A (labeled active comparator but a TB candidate the control didn't get), and non-adjuvanted M72 in saline."
},
{
"nct": "NCT00409188",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide (L-BLP25), a cancer vaccine in NSCLC."
},
{
"nct": "NCT00411749",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil (aluminium adjuvant); placebo unspecified."
},
{
"nct": "NCT00418574",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Abagovomab, an anti-idiotype antibody for ovarian cancer."
},
{
"nct": "NCT00420316",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Long-term follow-up (6 months in third year of life, SAEs only) of the Rota-036 randomized Rotarix and placebo arms; no further vaccination, groups kept by original randomization."
},
{
"nct": "NCT00420745",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Rotarix vs placebo in pre-term infants (patients=true for prematurity)."
},
{
"nct": "NCT00423046",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix vs Gardasil (active comparator); placebo doses only kept the blind."
},
{
"nct": "NCT00432380",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant EPI vaccines"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two Rotarix liquid schedules (each with one placebo dose) pooled vs 3 doses of placebo."
},
{
"nct": "NCT00434577",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got gE vaccine: EG003 got saline then gE/AS01B HD (AE period spans both); EG004, titled Placebo Group, got a modified gE formulation reconstituted with saline. No clean placebo group."
},
{
"nct": "NCT00435812",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEPLISAV vs Engerix-B (active comparator); saline only replaced HEPLISAV's third dose."
},
{
"nct": "NCT00437021",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006",
"EG007",
"EG008",
"EG009",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IMVAMUNE schedules A, B and F and the IMVAMUNE plus Dryvax schedules D and E, pooled against their saline placebo groups. Group C (Dryvax alone, EG002) is left out: no Placebo C group is reported. Groups are as treated.",
"third_reader_reason": "The coders differed on Group C (Dryvax alone): coder 1 pooled it with the others, coder 2 left it out. The tables report no placebo group for Group C, and note 17 leaves out cohorts with no placebo group of their own."
},
{
"nct": "NCT00439335",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H5N1 vaccine ID vs IM; saline only in the other arm to keep the blind, both groups vaccinated."
},
{
"nct": "NCT00442169",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is West Nile virus (other). ChimeriVax-WN02, a live chimeric attenuated virus; Part 1 doses and Part 2 pooled with both parts' saline placebo groups."
},
{
"nct": "NCT00456807",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ancillary immunogenicity study of Cervarix vs placebo recipients from a primary study; the record says no safety data were collected here."
},
{
"nct": "NCT00460525",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "FMP2.1/AS02A vs rabies vaccine (active control)."
},
{
"nct": "NCT00464334",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V950, an amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00468858",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two WRAIR live attenuated tetravalent dengue formulations pooled; placebo is a lyophilized product reconstituted with sterile water, contents not given."
},
{
"nct": "NCT00479557",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 (vanutide cridificar), an amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00480324",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rotarix vs placebo, 2 doses."
},
{
"nct": "NCT00481767",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04) vs Al(OH)3 placebo."
},
{
"nct": "NCT00485134",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "Shigella challenge about 42 days after the last dose"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 2 immunized (EG003) against Stage 2 controls (EG004), who were given a control by the same nasal device on the same schedule; the record's placebo is sterile saline. Adverse events are those after vaccination. Stage 1 dose groups (EG000 to EG002) have no placebo group of their own and are left out. Invaplex 50 is a complex of Ipa proteins and LPS in Tris-saline buffer, no adjuvant added.",
"third_reader_reason": "Coder 1 took Stage 2 immunized against Stage 2 controls; coder 2 excluded the trial because the controls are called non-immunized rather than placebo. The control arm is a placebo comparator given 'a control' by the same device on the vaccination schedule, and the record names the trial's placebo as sterile saline, so I read it as a saline placebo group and kept the Stage 2 comparison, leaving Stage 1 out under note 17."
},
{
"nct": "NCT00485732",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04) vs placebo of unstated composition."
},
{
"nct": "NCT00492557",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "trivalent inactivated influenza vaccine"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the first period only (13vPnC+TIV vs placebo+TIV); second-period groups (EG001, EG003) are after crossover and count the same participants again."
},
{
"nct": "NCT00493285",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other",
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Other target: parainfluenza virus type 3. MEDI-534 is a live attenuated chimeric bovine/human PIV3 carrying RSV F (coded live_attenuated as a chimeric attenuated virus). Three dose cohorts pooled with their placebo subgroups."
},
{
"nct": "NCT00496626",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil vs aluminium-containing placebo."
},
{
"nct": "NCT00498602",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001, an amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00503009",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Asthma inhalers (fluticasone/salmeterol) vs placebo with rhinovirus inoculation; no vaccine."
},
{
"nct": "NCT00508651",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is parainfluenza virus type 3 (other). MEDI-560 live attenuated rHPIV3cp45 vs sucrose phosphate buffer placebo."
},
{
"nct": "NCT00518336",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Long-term follow-up (SAEs only, to year 9) of Cervarix and placebo arms of a primary study; no vaccination in this study, groups by original randomization."
},
{
"nct": "NCT00518687",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V710 (recombinant IsdB protein, lyophilized formulation) vs matching placebo in patients scheduled for cardiothoracic surgery; adjuvant not stated in the record."
},
{
"nct": "NCT00521586",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "trivalent inactivated influenza vaccine"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the dose 1 groups only (13vPnC+TIV vs placebo+TIV, 1 month after dose 1); later groups follow the crossover to 13vPnC and the year 5 revaccination."
},
{
"nct": "NCT00529399",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GAD-alum (Diamyd), an antigen-specific immunotherapy for type 1 diabetes."
},
{
"nct": "NCT00534248",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Zostavax vs placebo of the vaccine's stabilizer without live virus."
},
{
"nct": "NCT00535236",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V212 heat-treated (inactivated) VZV vaccine vs placebo in immunocompromised adults (autologous HCT, allogeneic HCT, solid tumor, hematologic malignancy, HIV); population subgroups pooled."
},
{
"nct": "NCT00535730",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal",
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Zostavax with PPV23 concomitantly vs non-concomitantly; both groups got both vaccines, placebo only kept the schedule blind."
},
{
"nct": "NCT00538512",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two vaccines (Fluzone TIV IM, FluMist LAIV intranasal) against one saline placebo group, given as nasal spray or IM injection and reported as one group."
},
{
"nct": "NCT00539981",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "FluBlok recombinant HA (lots pooled) vs normal saline."
},
{
"nct": "NCT00541970",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix formulations and schedules compared; placebo doses only filled schedule slots."
},
{
"nct": "NCT00546078",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label: former vaccinees got a 4th Cervarix dose, former placebo recipients 3 doses; no placebo in this study."
},
{
"nct": "NCT00546819",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax vs placebo in people on chronic/maintenance corticosteroids."
},
{
"nct": "NCT00550745",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Zostavax vs placebo; only SAEs collected (to 182 days)."
},
{
"nct": "NCT00555893",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Oseltamivir vs placebo for influenza treatment; no vaccine."
},
{
"nct": "NCT00562484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CSL split-virion inactivated influenza vaccine (2008 or 2009 Southern Hemisphere formulation) vs placebo of unstated composition."
},
{
"nct": "NCT00566345",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vero cell-derived split-virus trivalent non-adjuvanted vaccine vs phosphate-buffered saline."
},
{
"nct": "NCT00572910",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG010"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V710 (IsdB) groups, split by Day 180 dose (V710 or placebo), pooled; together they count each participant once. MAA (Merck aluminium adjuvant) groups coded aluminium, groups without MAA none. Hemodialysis patients."
},
{
"nct": "NCT00574704",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "House dust mite allergen vaccine with CYT003-QbG10 (allergy immunotherapy)."
},
{
"nct": "NCT00586339",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Cervarix vs Al(OH)3 control in HIV-positive women; HIV-negative Cervarix group (EG002) left out, no placebo group in that population."
},
{
"nct": "NCT00596271",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "hepatitis A vaccine (Havrix)"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IC51 with Havrix (EG002) against placebo with Havrix (EG001): they differ only in IC51. EG000 (IC51 with placebo) is left out; its match would test Havrix and reuse EG002. IC51 is inactivated Japanese encephalitis vaccine on aluminium hydroxide (Ixiaro).",
"third_reader_reason": "Coder 1 compared IC51 plus Havrix with placebo plus Havrix; coder 2 excluded the trial as vaccine in every arm. EG002 and EG001 differ only in IC51 against placebo, and note 4 says to take the comparison testing the study vaccine the title and condition name (IC51) and leave the other out."
},
{
"nct": "NCT00605085",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IC51 (inactivated JE vaccine, aluminium hydroxide) vs PBS with 0.1% aluminium hydroxide."
},
{
"nct": "NCT00616928",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK H5N1 monovalent adjuvanted vaccine (split, AS03-adjuvanted Q-Pan; formulations A-C pooled), age cohorts 18-64 and >64 pooled. Only these four groups are reported."
},
{
"nct": "NCT00620815",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm got H5N1 vaccine (Aflunov) and/or MF59-eTIV-H5N1 across the study; placebo only accompanied a vaccine on day 1, and AE groups cover the whole study."
},
{
"nct": "NCT00621322",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got AS01B alone. GSK692342 (M72) formulations pooled: F1 non-adjuvanted (labeled active comparator); F2-F4 adjuvanted, adjuvant system not named per formulation, coded other (GSK692342 is M72/AS01)."
},
{
"nct": "NCT00622843",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Open-label PCV vs PPV23 in HIV; HIV-negative PCV group; no placebo."
},
{
"nct": "NCT00630331",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cell culture-derived and egg-derived subunit (surface antigen) influenza vaccines vs PBS; SAEs only."
},
{
"nct": "NCT00644059",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MF59-adjuvanted TIV vs non-adjuvanted TIV vs non-influenza control vaccines (MenC conjugate or TBE); all controls are active vaccines."
},
{
"nct": "NCT00659789",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Vacc-4x is a therapeutic HIV peptide vaccine given to HIV-infected people on ART."
},
{
"nct": "NCT00661713",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Schedule comparison of rMenB+OMV NZ; every arm, including rMenB6 (placebo months 0-2), gets the vaccine, and the AE groups span the whole study."
},
{
"nct": "NCT00677820",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated trivalent influenza vaccine; placebo is sucrose-phosphate buffer (with egg allantoic fluid per the AE group)."
},
{
"nct": "NCT00679172",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral live attenuated S. Typhi ZH9, four dose cohorts pooled against pooled excipient placebo."
},
{
"nct": "NCT00686075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other",
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MEDI-534 is a live bovine/human parainfluenza virus type 3 carrying the RSV F protein, coded viral_vector by note 2; target other = parainfluenza virus type 3. Five age and dose cohorts pooled. Placebo matched to the vaccine, composition not given.",
"third_reader_reason": "The coders differed on the platform: coder 1 listed live_attenuated and viral_vector, coder 2 live_attenuated alone. Note 2 names a parainfluenza virus carrying an RSV protein as viral_vector, and this is one vaccine, not two of different platforms, so I gave viral_vector alone."
},
{
"nct": "NCT00693654",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pramoxine lotion for uremic itch; no vaccine."
},
{
"nct": "NCT00696709",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part 1 only: heat-treated (EG000) and gamma-irradiated A (EG001) against the Part 1 placebo (EG002). Part 2 groups EG003 and EG004 had no placebo group of their own. V212 is inactivated varicella-zoster virus with no adjuvant.",
"third_reader_reason": "The coders differed on the Part 2 groups: coder 1 left them out, coder 2 pooled them against the Part 1 placebo. The placebo arm belongs to Part 1 and Part 2 had none, so note 17 leaves the Part 2 cohorts out."
},
{
"nct": "NCT00702221",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Angiotensin therapeutic vaccine for hypertension, a non-infectious target."
},
{
"nct": "NCT00706550",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Immediate vs delayed PPV23 with placebo crossover in HIV-infected adults; both arms get PPV23 and the AE groups are reported for the whole study, not the first period."
},
{
"nct": "NCT00707967",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG002"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "M72/AS01E in HIV-positive adults. Two placebo groups: EG001 is AS01E adjuvant alone, EG002 is saline; both put in one comparison (the vaccine group can't be in two), placebo_content set to adjuvant because one placebo holds it."
},
{
"nct": "NCT00718237",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq vs matching placebo in Japanese infants."
},
{
"nct": "NCT00719043",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group, including the naive placebo-first group, receives H5N1 vaccine during the study; the AE groups span the whole study, so the Day 0-182 placebo-controlled period is not reported separately."
},
{
"nct": "NCT00723489",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "YFV-17D subcutaneous vs transcutaneous, each with a placebo at the other site; every group gets the vaccine."
},
{
"nct": "NCT00735644",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "JE-CV lots compared with another JE-CV and a hepatitis A vaccine (Avaxim) control; no placebo."
},
{
"nct": "NCT00735839",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V710 (IsdB protein) vs saline in healthy Japanese men; the record does not state an adjuvant."
},
{
"nct": "NCT00736476",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': Helicobacter pylori infection, in H. pylori-negative adults (preventive). The record names Novartis' investigational H. pylori vaccine, whose published composition is recombinant VacA, CagA and NAP proteins with aluminium hydroxide (note 1). Placebo composition is not given in the record. Each group spans the whole study period and counts its participants once.",
"third_reader_reason": "The coders agreed on eligibility and groups and differed only in platform (other vs protein). By note 1 the maker's one investigational H. pylori vaccine is identified and its composition is published (recombinant VacA, CagA, NAP with aluminium hydroxide), so I coded protein, and aluminium rather than the unknown both gave."
},
{
"nct": "NCT00744263",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the safety set groups (all participants, SAEs to 1 month); the immunogenicity subset groups EG002 and EG003 report a subset of the same participants again and are left out. PCV13 holds aluminium phosphate."
},
{
"nct": "NCT00746798",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChimeriVax-WN02, a live attenuated chimeric yellow fever/West Nile virus; other target = West Nile virus. Three doses pooled vs saline."
},
{
"nct": "NCT00751777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Skin patch of E. coli heat-labile enterotoxin (LT) against ETEC travellers' diarrhoea; LT is the antigen and no separate adjuvant is added. The placebo is a patch with 0 mcg LT; what the patch holds is not given.",
"third_reader_reason": "The coders differed only on the placebo's content: inert (coder 1) or not_stated (coder 2). The record says the placebo patch holds no LT but not what it does hold, which is a matching placebo with no composition given, not_stated under note 8."
},
{
"nct": "NCT00752232",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00772954",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Alum-adsorbed C. difficile toxoid vaccine, two doses pooled, vs vaccine diluent buffer."
},
{
"nct": "NCT00777257",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Menactra and Tdap given together or a month apart; every group gets both vaccines within the AE period."
},
{
"nct": "NCT00779402",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sipuleucel-T, an autologous cellular vaccine for prostate cancer."
},
{
"nct": "NCT00779766",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04, aluminium) vs placebo of unstated composition in Chinese women."
},
{
"nct": "NCT00788151",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got two placebo injections and Pneumo23 as its third injection; the AE groups span all three, so the control is partly an active vaccine."
},
{
"nct": "NCT00800605",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vero cell-derived split trivalent influenza vaccine vs PBS."
},
{
"nct": "NCT00802464",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01 formulations pooled vs saline."
},
{
"nct": "NCT00808028",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat the same participants by period. Took the Stage 1 vaccination-period groups EG000 to EG003, which begin at the first dose and hold all four arms; the Stage 1 follow-up groups (EG004 to EG007) and the Stage 2 groups (EG008 to EG010, no 60 mcg arm) are left out. rLP2086 is recombinant lipoprotein with aluminium phosphate.",
"third_reader_reason": "The coders took different periods of the same participants: coder 1 the Stage 1 vaccination groups, coder 2 the Stage 1 follow-up groups. Note 6 says to take the groups that begin at the first vaccination and, for groups by period, the first period."
},
{
"nct": "NCT00819013",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2e influenza A vaccine with Alhydrogel, with QS-21, or without adjuvant, vs saline."
},
{
"nct": "NCT00822757",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Lyophilized V710 (IsdB protein) vs buffered saline; the record does not state an adjuvant."
},
{
"nct": "NCT00834106",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil vs an aluminium-containing placebo."
},
{
"nct": "NCT00836498",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq 3 doses vs matching placebo in elderly people; the Part II one-dose RotaTeq arm has no AE group of its own."
},
{
"nct": "NCT00841763",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TIV then aH5N1 vs placebo then aTIV; the control group gets an active adjuvanted influenza vaccine within the AE period."
},
{
"nct": "NCT00842530",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The control AE group pools Cohort 1 (rabies vaccine then placebo) with Cohort 2 (placebo only), so the placebo-only arm isn't reported on its own."
},
{
"nct": "NCT00848211",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TUTI-16 given to people already infected with HIV-1: a therapeutic HIV vaccine."
},
{
"nct": "NCT00849680",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MRKAd5 gag and gag/pol/nef doses and schedules pooled vs placebo in healthy adults. AE time frame not given."
},
{
"nct": "NCT00851786",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax vs placebo in HIV-infected adults on ART."
},
{
"nct": "NCT00857311",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Preventive MRKAd5 HIV-1 gag vaccine vs placebo in people with chronic hepatitis C; the 1x10^10 and Td arms enrolled no one."
},
{
"nct": "NCT00857493",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IMVAMUNE twice vs placebo then IMVAMUNE; both groups are vaccinated and the AE groups span the study."
},
{
"nct": "NCT00865566",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DNA prime then rAd5 boost vs PBS and final formulation buffer placebos."
},
{
"nct": "NCT00869778",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "epsilonPA-44 therapeutic hepatitis B vaccine for chronic hepatitis B."
},
{
"nct": "NCT00873912",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated monovalent B influenza vaccine vs sucrose-phosphate buffer."
},
{
"nct": "NCT00875524",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got meningococcal A+C polysaccharide, placebo, then Typhim Vi; active controls within the AE period."
},
{
"nct": "NCT00877448",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Multimeric-001 in PBS vs PBS, and Montanide-adjuvanted Multimeric-001 vs Montanide-adjuvanted PBS, kept as two comparisons since each pair differs only in the antigen and the placebos differ in content."
},
{
"nct": "NCT00879762",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "High vs standard dose IMVAMUNE; placebo only fills out the schedule."
},
{
"nct": "NCT00879814",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got Tdap at month 0 and saline at months 2 and 6; an active vaccine within the AE period."
},
{
"nct": "NCT00880698",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "RotaTeq vs placebo in HIV-infected and HIV-uninfected infants of HIV-infected mothers; HIV strata pooled."
},
{
"nct": "NCT00880893",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got placebo at month 0, then hepatitis A or influenza vaccine at months 6 and 12; the AE groups span all three."
},
{
"nct": "NCT00886613",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "VZV skin tests and intradermal saline"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V212 (inactivated VZV) and Zostavax each vs one placebo, so both are vaccine groups."
},
{
"nct": "NCT00920218",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01 formulations F1 and F2 (three doses) and the arm given saline then two F1 doses (EG002), a randomized arm on a two-dose schedule, against three doses of saline (EG003).",
"third_reader_reason": "The coders differed on EG002, the arm given one placebo dose and then two vaccine doses: coder 1 counted it as a vaccine group, coder 2 left it out as mixing arms. It is one randomized arm whose participants all got the vaccine on a different schedule, which the codebook counts as a vaccine group."
},
{
"nct": "NCT00925548",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide (L-BLP25), a cancer vaccine for breast cancer."
},
{
"nct": "NCT00929526",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Follow-up of Cervarix vs Aimmugen (hepatitis A vaccine) control; no placebo and no vaccination in this study."
},
{
"nct": "NCT00941889",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Gardasil given to HIV-positive patients treated for anal condylomata to prevent recurrence, i.e. against disease they already have; adverse events were also not collected."
},
{
"nct": "NCT00943878",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H1N1 vaccine and TIV given in different orders; every group gets both."
},
{
"nct": "NCT00945893",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat participants by period (Days 1-15, 29-57, 58-209); took Days 58-209 as the longest placebo-controlled follow-up."
},
{
"nct": "NCT00946101",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat participants by period (Days 1-28, 29-57, 58-209); took Days 58-209 as the longest placebo-controlled follow-up."
},
{
"nct": "NCT00950612",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M72/AS01E vs physiological saline in healthy adolescents."
},
{
"nct": "NCT00952276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Subvirion H1N1 vaccine with an unnamed adjuvant (EG000, EG001, adjuvant unknown) or without (EG002, EG003) vs saline."
},
{
"nct": "NCT00952419",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Unadjuvanted subvirion H1N1 vaccine, two doses pooled, vs saline in children."
},
{
"nct": "NCT00953056",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq vs matching placebo; adult, child and infant cohorts pooled."
},
{
"nct": "NCT00953524",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Unadjuvanted subvirion H1N1 vaccine, three doses pooled, vs saline."
},
{
"nct": "NCT00953927",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA85A against Candida skin test antigen (Candin), which the record calls a placebo control but is an immunologically active product.",
"third_reader_reason": "Coder 1 excluded the trial because the control is Candida skin test antigen; coder 2 took it as a placebo of unstated content. Note 8 says a skin-test antigen is not a placebo, so there is no placebo group."
},
{
"nct": "NCT00958126",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Adult and older-adult cohorts pooled into one comparison; placebo is vaccine diluent. CSL425 taken as unadjuvanted split H1N1 vaccine (no adjuvant named)."
},
{
"nct": "NCT00958243",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Age cohorts A and B pooled into one comparison. Placebo composition not given."
},
{
"nct": "NCT00959192",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 is an anti-amyloid vaccine for Alzheimer's disease (QS-21 adjuvant control)."
},
{
"nct": "NCT00960115",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide is a therapeutic cancer vaccine for NSCLC."
},
{
"nct": "NCT00968890",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get two doses of Pandemrix and one of Fluarix; placebo only shifts when Fluarix is given."
},
{
"nct": "NCT00969228",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo composition not given."
},
{
"nct": "NCT00969878",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TA-CD is a cocaine vaccine for treating cocaine dependence."
},
{
"nct": "NCT00971425",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get Pandemrix twice and Fluarix once; placebo only changes when Fluarix is given."
},
{
"nct": "NCT00974818",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Intravesical BCG given as bladder cancer treatment against mitomycin C; no placebo."
},
{
"nct": "NCT00975507",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"measles_mumps_rubella",
"varicella"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ProQuad (+ placebo dummy) against licensed M-M-R II + Varivax: active control."
},
{
"nct": "NCT00981175",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover (vaccine then diluent vs diluent then vaccine at Day 28); AE groups cover both periods (6 months), so the first, placebo-controlled period isn't reported alone. EG002 is a booster group."
},
{
"nct": "NCT00981630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three dose levels pooled; ChimeriVax-JE is a chimeric live attenuated virus; placebo is ChimeriVax diluent."
},
{
"nct": "NCT00981669",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Butantan rotavirus vaccine in adults; record doesn't name its platform, taken as live oral rotavirus vaccine. Placebo composition not given."
},
{
"nct": "NCT00982137",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"japanese_encephalitis",
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets both ChimeriVax-JE and STAMARIL; arms differ only in order and co-administration; AE groups span both visits."
},
{
"nct": "NCT00985088",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets an H1N1 vaccine; saline only replaces a second dose."
},
{
"nct": "NCT00985166",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "M-M-R II"
}
],
"targets": [
"varicella"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Varivax with M-M-R II (EG002) against placebo with M-M-R II (EG001): they differ only in Varivax. EG000 (ProQuad with placebo) is left out, since ProQuad against M-M-R II is an active comparison.",
"third_reader_reason": "Coder 1 compared Varivax plus M-M-R II with placebo plus M-M-R II; coder 2 excluded the trial as having only active controls. The two arms differ only in a licensed vaccine against placebo, which note 9 counts as a vaccine group and its placebo group, so the trial stays, with varicella as the target."
},
{
"nct": "NCT00985426",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HEPLISAV-B against licensed Engerix-B in chronic kidney disease; saline only blinds the schedule."
},
{
"nct": "NCT00985673",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets Flulaval and two doses of Arepanrix (adjuvanted or not); saline only shifts timing."
},
{
"nct": "NCT00992433",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Two dose levels of H1N1 vaccine in HIV-infected adults; no placebo arm."
},
{
"nct": "NCT00993447",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The control arm got saline at the first two injections and Adacel at the third, and its one group covers all three injections, so it is not a placebo group and no group covers only the saline doses.",
"third_reader_reason": "Coder 1 excluded the trial because the control group's adverse events include those after Adacel; coder 2 kept it as an inert placebo. A control group that also got an active vaccine the dengue arm did not get differs in more than the study vaccine, and no group reports the saline-controlled doses alone, so no clean comparison remains."
},
{
"nct": "NCT00993668",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests certolizumab pegol's effect on influenza and pneumococcal vaccine responses in rheumatoid arthritis; every arm gets the vaccines."
},
{
"nct": "NCT00995865",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups are reported per injection; took the first-injection groups (EG000-EG002), which count every randomized participant once; second-injection groups EG003-EG005 left out (same participants). Placebo is 0.9% NaCl."
},
{
"nct": "NCT00996125",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix holds AS04 (aluminium hydroxide + MPL). Placebo composition not given."
},
{
"nct": "NCT01001325",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Fluviral is an unadjuvanted split seasonal vaccine; placebo is normal saline."
},
{
"nct": "NCT01005407",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEPLISAV against licensed Engerix-B; saline only blinds the third visit."
},
{
"nct": "NCT01009645",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral trial of educational messages on influenza vaccine uptake; no vaccine is given as an intervention."
},
{
"nct": "NCT01009762",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AFO-18 is a therapeutic HIV peptide vaccine in chronic HIV infection."
},
{
"nct": "NCT01011335",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG012"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All rAT, rLukS-PV and bivalent dose groups against the saline placebo (EG012). The alum placebo (EG011) is left out under note 5. The vaccines' alum is inferred from the 'placebo with adjuvant' arm; the record does not state it outright.",
"third_reader_reason": "The coders differed on the placebo groups: coder 1 pooled the alum and saline placebos as adjuvant, coder 2 took the alum placebo alone. Note 5 says that when an inert and an adjuvant placebo serve the same vaccine groups, the inert one is taken and the adjuvant one left out, so I took the saline group alone, as neither coder did."
},
{
"nct": "NCT01015443",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide is a therapeutic cancer vaccine for NSCLC."
},
{
"nct": "NCT01017536",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AERAS-402 is an Ad35 vector; placebo is its formulation buffer. HIV-infected, BCG-vaccinated adults."
},
{
"nct": "NCT01035749",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets Arepanrix (adjuvanted or not); saline only replaces a dose."
},
{
"nct": "NCT01047345",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took base-study groups; EG002 (open-label 9vHPV in the extension, former placebo recipients) left out. V503 holds AAHS; placebo is saline."
},
{
"nct": "NCT01051661",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets an H1N1 vaccine; placebo only replaces a second dose."
},
{
"nct": "NCT01059617",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the pooled Day 0 groups, Flulaval (EG004) vs saline (EG005), the placebo-controlled period. EG000-EG003 left out: the same participants again, for the period when every arm got Arepanrix."
},
{
"nct": "NCT01067781",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Skin patch of E. coli heat-labile enterotoxin (LT) against ETEC travellers' diarrhoea, applied with and without skin swabbing, each with its own placebo patch; the two are pooled as ways of applying one product. LT is the antigen and no separate adjuvant is added. Placebo patch with 0 mcg LT, contents not given.",
"third_reader_reason": "The coders differed on whether swabbing splits the trial into two comparisons (coder 1) or leaves one (coder 2), and on the adjuvant: none (coder 1) or unknown (coder 2). Swabbing is a way of applying the patch, not a co-administered product, so I pooled as coder 2 did; the patch holds LT alone with no added adjuvant, so none, as coder 1 gave."
},
{
"nct": "NCT01080716",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part 1 (WRSS1 vs placebo). Part 2 challenge groups EG002 (vaccinees, same participants) and EG003 (naive controls) left out."
},
{
"nct": "NCT01104493",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent intranasal FluMist; placebo is the sucrose phosphate/gelatin-arginine-glutamate buffer."
},
{
"nct": "NCT01134263",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Four CYD-TDV lots pooled; placebo is NaCl 0.9%."
},
{
"nct": "NCT01141205",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AFO-18 therapeutic HIV peptide vaccine in HIV-infected people (CDC group I) to prevent progression to disease."
},
{
"nct": "NCT01144637",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three IMVAMUNE (MVA-BN) lots pooled; placebo is Tris-buffered saline."
},
{
"nct": "NCT01147068",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Recombinant H5N1 hemagglutinin (PanBlok) at several doses, with or without GLA-SE (TLR4 agonist in oil-in-water emulsion, no aluminium), against 0.9% saline; doses pooled into one comparison."
},
{
"nct": "NCT01150123",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG011",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG014",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
},
{
"id": "EG016",
"platforms": [
"polysaccharide"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG008",
"EG017"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All doses, one or two injections, and no-adjuvant, alum and MF59 formulations pooled against both saline placebo groups. The record says only 'GBS vaccine'; the platform (capsular polysaccharide conjugated to CRM197) is from what is known of the product.",
"third_reader_reason": "The coders differed only on the platform: other (coder 1) or polysaccharide (coder 2). The GBS vaccine tested in dose-ranging trials with alum and MF59 is the capsular polysaccharide-CRM197 conjugate, which I am confident of, so note 1 allows polysaccharide."
},
{
"nct": "NCT01151189",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MVA85A (MVA carrying Ag85A). Placebo is Candin, a Candida albicans skin-test antigen: not inert and not an adjuvant, so set to not_stated. HIV-infected adults."
},
{
"nct": "NCT01165177",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01B (Shingrix); placebo is NaCl solution."
},
{
"nct": "NCT01165203",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "gE/AS01B in HIV-infected adults. Placebo composition not given."
},
{
"nct": "NCT01165229",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01B (Shingrix); placebo is NaCl solution."
},
{
"nct": "NCT01168401",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004",
"EG006",
"EG008",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLP vaccine with MPL + Al(OH)3; cohorts A-D (doses and ages) pooled with their saline placebo groups."
},
{
"nct": "NCT01171963",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant vaccines (Infanrix, OPV)"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Liquid Rotarix vs placebo, both with EPI Infanrix and OPV. Placebo composition not given."
},
{
"nct": "NCT01173653",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Smoking-cessation counseling trial in emergency department patients; no vaccine."
},
{
"nct": "NCT01181323",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "LAIV vs TIV in postpartum breastfeeding women, double-dummy placebos; active control. Infant groups likewise have no placebo."
},
{
"nct": "NCT01187433",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Arm and AE group say the control got 3 injections of NaCl 0.9%, but the control arm's intervention list also names Adacel and meningococcal A+C vaccine without saying when; taken as placebo per the AE group description. A second reader should check this."
},
{
"nct": "NCT01193920",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Non-pregnant women (two doses with aluminium; first comparison) and pregnant women (one unadjuvanted dose; second) are reported apart and kept as two comparisons; the infants of the pregnant women are the offspring comparison. The trivalent GBS vaccine is capsular polysaccharide conjugated to CRM197, from what is known of the product.",
"third_reader_reason": "The coders differed on whether non-pregnant and pregnant women form two comparisons (coder 1) or one (coder 2), and on the platform: other (coder 1) or polysaccharide (coder 2). Note 14 calls for two comparisons when the tables report them apart, and the trivalent GBS vaccine is a known polysaccharide conjugate, so I took coder 1's comparisons with coder 2's platform."
},
{
"nct": "NCT01198366",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Dose-finding (2 doses) and expanded safety phase (3 doses) pooled; placebo is sterile buffer. Infants had BCG before the study."
},
{
"nct": "NCT01199861",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests fingolimod's effect on responses to influenza and tetanus vaccines that every arm gets, in multiple sclerosis."
},
{
"nct": "NCT01203319",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "60, 30 and 10 mcg hepatitis B vaccine in prior non-responders; the 'placebo comparator' is the 10 mcg vaccine."
},
{
"nct": "NCT01214837",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label MenACWY-CRM + routine vaccines vs routine vaccines alone; no placebo."
},
{
"nct": "NCT01214850",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Japanese encephalitis vaccine (IXIARO), an active control; placebo only fills MenACWY's second visit."
},
{
"nct": "NCT01218113",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccine in ART-naive HIV-infected people."
},
{
"nct": "NCT01224639",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDV (TAK-003 precursor) low/high dose by SC/ID route pooled with their PBS placebo groups."
},
{
"nct": "NCT01227564",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 anti-amyloid vaccine for Alzheimer's disease."
},
{
"nct": "NCT01229267",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Inactivated VZV vaccine V212, all lots pooled as reported; placebo is the vaccine stabilizer without antigen, so taken as unadjuvanted."
},
{
"nct": "NCT01245764",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo arm exists only in the 9-12 year cohort; took Gardasil 9-12 (EG000) vs placebo 9-12 (EG003). Gardasil 13-15 and 16-26 (EG001, EG002) left out: no placebo in their age cohorts. Gardasil holds amorphous aluminium hydroxyphosphate sulfate."
},
{
"nct": "NCT01254422",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01254630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Solid-tumour and haematologic-malignancy strata pooled. V212 is inactivated varicella-zoster virus with no adjuvant; the placebo is the vaccine's stabilizer with no virus antigen.",
"third_reader_reason": "The coders differed only on the placebo's content: inert (coder 1) or not_stated (coder 2). The record gives it as the vaccine stabilizer with no virus antigen, which is the vaccine's excipients without antigen or adjuvant, so inert."
},
{
"nct": "NCT01262976",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled HIV+ on HAART, HIV+ HAART-naive and HIV- strata. GSK692342 is the M72 fusion protein with AS01 (record names only the code)."
},
{
"nct": "NCT01263691",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"anthrax"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BioThrax (AVA, aluminium hydroxide) and four AV7909 formulations (AVA + CpG 7909) all against saline; BioThrax included as a second vaccine against the same placebo. Record says other-AE frequency thresholds used all arms combined."
},
{
"nct": "NCT01264601",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both arms get TIV; compares single dose vs graded challenge in egg-allergic children."
},
{
"nct": "NCT01265433",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "WT-1 peptide cancer vaccine in mesothelioma; control is Montanide + GM-CSF."
},
{
"nct": "NCT01272180",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get meningococcal vaccines; MenACWY group got placebo then MenACWY, and AE groups cover the whole period."
},
{
"nct": "NCT01274897",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenACWY-CRM (CRM197 conjugate, no adjuvant) vs saline."
},
{
"nct": "NCT01280552",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dendritic-cell glioblastoma vaccine."
},
{
"nct": "NCT01280903",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Behavioural physical-activity intervention, no vaccine."
},
{
"nct": "NCT01280968",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Anti-nicotine (addiction) vaccine vs alum placebo."
},
{
"nct": "NCT01299480",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All five groups get rLP2086 on different schedules, saline only filling visits."
},
{
"nct": "NCT01310413",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took pooled blinded-phase groups EG000 vs EG001. EG002 (placebo recipients vaccinated in the unblinded phase) left out as post-crossover. GSK H5N1 split-virion vaccine with AS03."
},
{
"nct": "NCT01322490",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "PROSTVAC prostate cancer vaccine."
},
{
"nct": "NCT01323270",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "Repevax (Tdap-IPV) at month 0"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent rLP2086 (aluminium phosphate) vs saline, both with Repevax."
},
{
"nct": "NCT01326546",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic hepatitis B vaccine with entecavir in chronic HBV."
},
{
"nct": "NCT01335191",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TUTI-16 in HIV-1-infected people on ART with a treatment interruption: a therapeutic HIV vaccine."
},
{
"nct": "NCT01352793",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Havrix (active vaccine) with one saline dose."
},
{
"nct": "NCT01352845",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent rLP2086 (aluminium phosphate) vs saline."
},
{
"nct": "NCT01359150",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests tofacitinib vs placebo for its effect on influenza and pneumococcal vaccines that every arm receives (could also be coded vaccine_in_every_arm)."
},
{
"nct": "NCT01367158",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Extension: third dose of meningococcal vaccine vs Tdap as control; no placebo group."
},
{
"nct": "NCT01373281",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01374516",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01385566",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets Zostavax; the Placebo group (EG006) is the saline-injected limb of vaccinated participants."
},
{
"nct": "NCT01411241",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups get CYD; only Pentaxim timing differs."
},
{
"nct": "NCT01424501",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled TB-treatment, TB-treated and TB-naive cohorts. Safety study of a preventive candidate (M72/AS01, named only GSK692342) in people with current or past TB disease, not given as treatment."
},
{
"nct": "NCT01424644",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Tdap (Boostrix) and HPV (Gardasil)"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenACWY-CRM vs placebo, both with Tdap and qHPV."
},
{
"nct": "NCT01436357",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Other = hepatitis C (prophylactic ChAd3-NSmut prime, MVA-NSmut boost). Placebo is sodium chloride. Analysed as treated."
},
{
"nct": "NCT01436396",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo group gets placebo only at injection 1 and CYD at months 6 and 12, inside the reported AE period; no placebo-only groups."
},
{
"nct": "NCT01446289",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Mothers EG000 vs EG001; infants EG002 vs EG003 as offspring. Trivalent GBS conjugate; adjuvant not stated."
},
{
"nct": "NCT01447407",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"other",
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Other = Candida (NDV-3, rAls3 protein). Arm and intervention say the placebo is alum in PBS; the AE group calls it saline given ID. Coded adjuvant by the arm description."
},
{
"nct": "NCT01461096",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "qHPV vs placebo in HIV-infected adults."
},
{
"nct": "NCT01461980",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "MCV4 and Tdap at month 0"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rLP2086 vs saline, both with MCV4+Tdap. EG002 (rLP2086 with saline in place of MCV4+Tdap, given those at month 7) left out."
},
{
"nct": "NCT01461993",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "Gardasil at months 0, 2, 6"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took rLP2086 vs saline on a Gardasil background (EG000 vs EG002). EG001 (rLP2086 + saline) left out: EG000 can serve only one comparison; the alternative was Gardasil vs saline on rLP2086 (EG000 vs EG001)."
},
{
"nct": "NCT01462357",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix vs Gardasil schedules; placebo only fills a visit."
},
{
"nct": "NCT01489020",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "House-dust-mite allergen immunotherapy."
},
{
"nct": "NCT01489527",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv",
"hpv"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "Gardasil vs placebo tested to reduce HIV infection (off target), also its own HPV target."
},
{
"nct": "NCT01501162",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Probiotics in alcoholic hepatitis; no vaccine, and AEs not collected."
},
{
"nct": "NCT01505166",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Autologous tumour-cell (Vigil/FANG) cancer vaccine."
},
{
"nct": "NCT01507779",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-virion inactivated H1N1 (IVACFLU) vs PBS; formulation given in full with no adjuvant, coded none."
},
{
"nct": "NCT01509846",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled four dose cohorts of oral killed whole-cell S. flexneri 2a vs pooled placebo; no adjuvant in the record, coded none."
},
{
"nct": "NCT01511250",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Part I age cohorts and Part II. TAK-003 (TDV) vs matching placebo."
},
{
"nct": "NCT01511419",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups are reported by dose for the same participants; took the dose 1 groups (EG000, EG001) and left out the dose 2 groups (EG002, EG003). The placebo is saline passed through eggs and prepared like the vaccine.",
"third_reader_reason": "The coders took different doses of the same participants: coder 1 the dose 1 groups, coder 2 the dose 2 groups. Note 6 says that for groups by dose the first dose is taken."
},
{
"nct": "NCT01527383",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V212 inactivated VZV (no adjuvant) vs placebo in adults with autoimmune disease."
},
{
"nct": "NCT01529645",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get aP or Tdap formulations; saline only fills a visit."
},
{
"nct": "NCT01537185",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Inactivated whole-cell pneumococcal vaccine with alum, three doses, vs saline."
},
{
"nct": "NCT01542632",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get TDV on different schedules or formulations."
},
{
"nct": "NCT01545375",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Prevnar 13 (and PedvaxHIB in a subset)"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "dPly-PhtD protein vaccine vs placebo, both with Prevnar 13; adjuvant not stated."
},
{
"nct": "NCT01546571",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Melanoma vaccine."
},
{
"nct": "NCT01550289",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01567306",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Grass-pollen allergen immunotherapy."
},
{
"nct": "NCT01570036",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "E75 HER2 peptide cancer vaccine with trastuzumab."
},
{
"nct": "NCT01579916",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal cold-adapted attenuated 6:2 reassortant trivalent vaccine vs sucrose-phosphate buffer placebo."
},
{
"nct": "NCT01609257",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "experimental norovirus GII.4 challenge"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent norovirus VLP with MPL and Al(OH)3 vs saline, both followed by challenge."
},
{
"nct": "NCT01610414",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK1437173A (Shingrix, gE/AS01B) vs saline. Record names no condition for enrolment, so patients false."
},
{
"nct": "NCT01616693",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"polio",
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests zinc and probiotic supplements on Rotarix and OPV that every arm receives (could also be coded vaccine_in_every_arm)."
},
{
"nct": "NCT01625689",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SII intranasal LAIV vs placebo of identical ingredients without virus."
},
{
"nct": "NCT01662440",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "Japanese encephalitis vaccine on days 1 and 29"
}
],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rabies with JE vaccine, conventional schedule (EG000), against saline with JE vaccine (EG003): they differ only in the rabies vaccine. EG000 can serve once; the other pairing (EG000 against EG002) would test the JE vaccine. EG001 (accelerated) has no matched placebo group. The rabies vaccine is inactivated whole virus with no adjuvant.",
"third_reader_reason": "Both coders took one comparison around EG000, but coder 1 tested the rabies vaccine against saline on a JE vaccine background and coder 2 the JE vaccine on a rabies background, with the placebo not stated. The title and conditions name rabies first and the record details the rabies vaccine as the study product, so by note 4 I took the rabies comparison; the record gives the placebo as 0.9% sodium chloride, so inert."
},
{
"nct": "NCT01666652",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDENV-PIV with alum (1 and 4 ug), AS01E or AS03B vs PBS."
},
{
"nct": "NCT01682876",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "One vs two MenACWY-CRM doses; all get vaccine. EG004 is a total."
},
{
"nct": "NCT01687595",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HSV-2 vaccine (HerpV + QS-21) in recurrent genital herpes."
},
{
"nct": "NCT01694108",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "BCG at birth given for its non-specific effect on childhood morbidity (target 'other': general childhood morbidity and infections, not tuberculosis). Control children got no intervention ('no suitable placebo exists')."
},
{
"nct": "NCT01697800",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tadalafil vs placebo in head and neck cancer; no vaccine."
},
{
"nct": "NCT01704781",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Vacc-4x is a therapeutic HIV vaccine given to HIV-infected people on ART; every arm gets it and the trial tests lenalidomide vs placebo."
},
{
"nct": "NCT01719783",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups reported per dose; took the Dose 1 groups (EG000, EG001), which include every randomized participant; Dose 2 groups re-count them."
},
{
"nct": "NCT01723254",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Anti-IgE vaccine for allergic rhinitis: non-infectious target."
},
{
"nct": "NCT01733056",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Every group gets Fluzone; groups are healthy volunteers vs patients on immunosuppressants, pre/post vaccination, not randomized to placebo."
},
{
"nct": "NCT01734811",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": true,
"note": "Sublingual bacterial vaccine spray given daily for six months to toddlers with recurrent wheezing; target other = recurrent wheezing attacks (bronchospasm with bronchiolitis or bronchitis). Bacterial vaccines given under the tongue are killed whole bacteria, coded inactivated by note 2; adjuvant not stated. Placebo spray, composition not given.",
"third_reader_reason": "The coders differed only on off_target. The bacterial vaccine was given to prevent wheezing attacks, not infection by its own bacteria, so by note 12 off_target is true, as coder 1 had it. Both coders gave platform other; note 2 makes killed whole bacteria given under the tongue inactivated, so I changed that."
},
{
"nct": "NCT01739231",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part A groups (EG000-EG002). Part B challenge groups (EG003-EG005) re-count Part A participants, and EG005 adds controls not randomized in Part A. EG001 got ACE527 with dmLT, a mucosal adjuvant, kept as the vaccine's adjuvant ('other'). Placebo is CeraVacx buffer (rice syrup, bicarbonate, citrate), the vaccine's buffer."
},
{
"nct": "NCT01745822",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Tenofovir vs placebo in HBV-infected pregnant women; infants' HBV immunization is background in both arms."
},
{
"nct": "NCT01755598",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M72/AS01E (AS01 adjuvant)."
},
{
"nct": "NCT01764256",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Saline placebo."
},
{
"nct": "NCT01765426",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All four groups get TDV; PBS placebo only fills in doses to compare schedules and devices."
},
{
"nct": "NCT01767467",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HZ/su (Shingrix, AS01B) in adults with haematologic malignancies."
},
{
"nct": "NCT01773395",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GVAX leukaemia cell vaccine: cancer vaccine."
},
{
"nct": "NCT01777295",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HBsAg/AS vs Engerix-B (active control); the Day -30 placebo dose is given to both groups."
},
{
"nct": "NCT01797029",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is the LAIV's ingredients with the viruses replaced by egg allantoic fluid; coded inert (excipients, no antigen)."
},
{
"nct": "NCT01798056",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HZ/su (Shingrix, AS01B) in adults with solid tumours on chemotherapy."
},
{
"nct": "NCT01802086",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "EMLA vs placebo cream for pain at a pneumococcal vaccination every infant gets."
},
{
"nct": "NCT01813071",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG008"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Live oral S. sonnei WRSS1; adult and child cohorts and doses pooled into one comparison with each part's placebo group."
},
{
"nct": "NCT01824537",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Avaxim (hepatitis A vaccine, active control) with a saline dose added to match the schedule."
},
{
"nct": "NCT01825200",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flublok vs Afluria (licensed IIV, active control) despite the 'Placebo Comparator' label."
},
{
"nct": "NCT01830855",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got Havrix (hepatitis A vaccine) plus one saline dose: active control."
},
{
"nct": "NCT01842360",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MV130 (Bactek), sublingual polyvalent whole-cell inactivated bacterial vaccine, in COPD; target 'other' = COPD exacerbations/respiratory bacterial infections. Platform and no adjuvant from what is known of MV130, not stated in the record."
},
{
"nct": "NCT01854632",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is the LAIV's ingredients with the viruses replaced by egg allantoic fluid; coded inert."
},
{
"nct": "NCT01859143",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal trivalent vaccine dosed in FFU: live attenuated influenza vaccine."
},
{
"nct": "NCT01859325",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccine (HIV-MAG pDNA + IL-12 pDNA prime, rVSV boost) in HIV-infected patients on ART."
},
{
"nct": "NCT01862874",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil (AAHS); placebo formulated with AAHS adjuvant."
},
{
"nct": "NCT01865487",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H56:IC31 (IC31 adjuvant); 2-dose and 3-dose schedules and their placebo groups pooled. Placebo is Tris-NaCl buffer. Participants with and without latent TB infection, not enrolled for a disease, so patients false."
},
{
"nct": "NCT01877655",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP0113 given to CMV-seropositive stem-cell transplant recipients, who already carry the virus; the record calls it a therapeutic vaccine.",
"third_reader_reason": "Coder 1 kept the trial as prevention of CMV disease; coder 2 excluded it as therapeutic. Note 10 names a cytomegalovirus vaccine in seropositive transplant patients as not preventive."
},
{
"nct": "NCT01887912",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sanofi C. difficile toxoid vaccine; aluminium hydroxide adjuvant from what is known of the product, not stated in the record. Enrolled adults at risk of C. difficile infection (impending hospitalization or recent hospital stays with antibiotics), so patients true."
},
{
"nct": "NCT01892345",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Eculizumab (antibody) vs placebo in NMO."
},
{
"nct": "NCT01895855",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "Vibrio cholerae challenge 10 days or 3 months after vaccination"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PXVX0200 (CVD 103-HgR) vs saline; both arms challenged."
},
{
"nct": "NCT01900665",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Solanezumab (passive immunization, antibody) in Alzheimer's disease."
},
{
"nct": "NCT01922921",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HER2 peptide cancer vaccine in every arm; trial tests polysaccharide-K vs placebo."
},
{
"nct": "NCT01926028",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target 'other' = recurrent vulvovaginal candidiasis (Candida). Kept as preventive: given to prevent recurrences, not to treat a current infection. Placebo is aluminium hydroxide in buffered saline."
},
{
"nct": "NCT01928225",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "qHPV given to HIV-infected women with cervical HSIL to improve the response to LEEP treatment: used against a lesion they already have (HPV-lesion use)."
},
{
"nct": "NCT01949090",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK H7N1 vaccine, four formulations whose content the record does not give; coded inactivated (GSK's IM influenza vaccines are split virion), adjuvant unknown."
},
{
"nct": "NCT01973218",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got saline at Day 1 and MenACWY-CRM at Day 31, and the groups report Days 1-61 as a whole, so the control group includes an active vaccine; EG002 is a total."
},
{
"nct": "NCT01974206",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP0113 in CMV-seronegative kidney recipients of organs from seropositive donors, so preventive. Platform (two plasmids) and adjuvant (poloxamer CRL1005 with benzalkonium chloride) are from what is known of ASP0113, not the record. Placebo composition not given.",
"third_reader_reason": "The coders differed only on the adjuvant: other (coder 1) or none (coder 2). ASP0113 is published as plasmid DNA formulated with the poloxamer CRL1005 and benzalkonium chloride, an adjuvant mixed with the vaccine, which note 3 codes other."
},
{
"nct": "NCT01981616",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"cholera",
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vedolizumab vs placebo; both arms get HBVAXPRO and Dukoral."
},
{
"nct": "NCT01982331",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is a lyophilizate of the vaccine's stabilizers."
},
{
"nct": "NCT01986010",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG011",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG013",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG015",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG007",
"EG014",
"EG016"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': V160 is a replication-defective whole-virus HCMV vaccine (from what is known of it; record names only V160). Serostatus strata, doses, routes (IM/ID) and MAPA formulations pooled with all four placebo groups; MAPA groups aluminium, others none."
},
{
"nct": "NCT01989572",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Melanoma peptide vaccine and GM-CSF: cancer."
},
{
"nct": "NCT01992536",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG006",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Extension of V102_03: participants randomized again to a booster or saline; the tables report only this later randomization, so it is used. Priming strata pooled; EG010 (total) left out. MenABCWY = rMenB+OMV (aluminium hydroxide, as in Bexsero) plus MenACWY-CRM conjugate."
},
{
"nct": "NCT01997229",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Eculizumab (antibody) in myasthenia gravis."
},
{
"nct": "NCT02010203",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HS-410 bladder cancer cell vaccine; BCG given as bladder cancer therapy."
},
{
"nct": "NCT02017899",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': 1790GAHB is a GMMA (outer membrane vesicle) S. sonnei vaccine; aluminium hydroxide (Alhydrogel) from what is known of the product, not in the record."
},
{
"nct": "NCT02041325",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Lenalidomide vs placebo around a hepatitis B vaccine every patient gets."
},
{
"nct": "NCT02046148",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal groups only; infants are not reported as separate groups, so no offspring comparison. The control is normal saline despite the 'Active Comparator' label. The record's composition of the vaccine names no adjuvant, and the trivalent GBS conjugate was given to pregnant women without one.",
"third_reader_reason": "The coders differed only on the adjuvant: unknown (coder 1) or none (coder 2). The record gives the vaccine's composition with no adjuvant in it, and the trivalent GBS conjugate was given to pregnant women in its unadjuvanted formulation, so none."
},
{
"nct": "NCT02058589",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HZ/su (AS01B) in renal transplant recipients; placebo is lyophilised sucrose in saline."
},
{
"nct": "NCT02062385",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant vaccines (OPV, DTaP), staggered or concomitant"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq; each group pools the staggered and concomitant EPI arms."
},
{
"nct": "NCT02071095",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Poly-ICLC (immune stimulant alone) in chronic HIV infection."
},
{
"nct": "NCT02075203",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two vaccines against one saline placebo: H4:IC31 (two doses) and BCG revaccination (one dose), both tested for prevention of infection. The placebo follows H4:IC31's schedule; the BCG arm was open label.",
"third_reader_reason": "The coders differed on the BCG arm: coder 1 took it as a second vaccine group, coder 2 left it out for lack of a matched placebo. The trial tests both H4:IC31 and BCG revaccination against its placebo arm, and the codebook puts every vaccine tested against one placebo in the comparison (note 9 likewise for a licensed vaccine), so BCG is in."
},
{
"nct": "NCT02075541",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target 'other' = non-typeable Haemophilus influenzae; NTHi protein vaccine with AS01E in COPD patients."
},
{
"nct": "NCT02094586",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took 'All PXVX0200 Lots' (EG003), which holds the same participants as lots A to C (EG000 to EG002); the record says only serious events were analysed by lot. If EG003's serious-event table is empty, the per-lot groups hold those counts.",
"third_reader_reason": "The coders took the same participants in different groups: coder 1 the pooled all-lots group, coder 2 the three lot groups. Either counts each participant once, but the record says non-serious events were not analysed by lot, so the pooled group is the one that covers them."
},
{
"nct": "NCT02097472",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "Synflorix (PCV10) and Pentavac (DTwP-HepB-Hib)"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Adults: wSP vs saline. Toddlers: wSP plus Synflorix and Pentavac vs saline plus the same vaccines. Toddler wSP+saline groups (EG004, EG006) left out: no group got saline alone to match them."
},
{
"nct": "NCT02100631",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Historical control arm is not in the AE groups."
},
{
"nct": "NCT02109484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toddler and infant cohorts and doses pooled with both placebo groups. Aluminium hydroxide from what is known of P2-VP8, not stated in this record."
},
{
"nct": "NCT02111577",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "DCVAC/PCa dendritic cell cancer vaccine."
},
{
"nct": "NCT02115815",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV sF alone (none) and MEDI7510 (sF with GLA-SE, 'other') at three doses vs saline."
},
{
"nct": "NCT02116205",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Hantaan/Puumala DNA vaccine (target 'other' = hantavirus, HFRS) in every arm; saline only replaces the Day 28 dose to compare schedules."
},
{
"nct": "NCT02117570",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "C. difficile toxoid vaccine, two dose levels and two age cohorts pooled against saline. The record doesn't name the product or say whether the formulation held aluminium hydroxide.",
"third_reader_reason": "The coders differed only on the adjuvant: aluminium from product knowledge (coder 1) or unknown (coder 2). The record names no product or adjuvant, and C. difficile toxoid vaccines were studied both with and without aluminium hydroxide, so I am not confident which this was, and note 1 then calls for unknown."
},
{
"nct": "NCT02117934",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEPLISAV vs Engerix-B, an active control; HEPLISAV's week-24 saline only fills the schedule."
},
{
"nct": "NCT02124161",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "seasonal inactivated influenza vaccine (QIV)"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the 'After Vaccination 1' groups (Day 1 to before Vaccination 2), before the placebo arm got 13vPnC; later-period and 'after 13vPnC' groups left out. Prevnar 13 holds aluminium phosphate."
},
{
"nct": "NCT02130882",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Benralizumab, an antibody; no vaccine."
},
{
"nct": "NCT02134925",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MUC1 peptide vaccine against colorectal adenoma and cancer, a non-infectious target."
},
{
"nct": "NCT02140762",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm got placebo then MenACWY at month 2, and the AE groups cover the whole study, so the control group includes an active meningococcal vaccine; no group for the placebo-only period is reported."
},
{
"nct": "NCT02142504",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo arm got the norovirus vaccine at Day 365, inside the AE window (Days 365-393, SAEs to Day 545); only whole-study groups are reported, none for the placebo-controlled first year alone."
},
{
"nct": "NCT02147587",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests tofacitinib vs placebo for its effect on a zoster vaccine every arm got."
},
{
"nct": "NCT02153112",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got the norovirus VLP vaccine; placebo only replaces a later dose (1 vs 2, or 2 vs 3 doses)."
},
{
"nct": "NCT02171819",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Inactivated H5N1 vaccine with aluminium hydroxide at 7.5 and 15 mcg HA, pooled, vs phosphate-buffered saline."
},
{
"nct": "NCT02187055",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tofacitinib and adalimumab in rheumatoid arthritis; no vaccine."
},
{
"nct": "NCT02190747",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Palovarotene in FOP; no vaccine."
},
{
"nct": "NCT02193087",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got a TDV formulation; placebo only replaces Group A's second dose."
},
{
"nct": "NCT02195349",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GSK2831781 is an IV biologic (antibody) tested in healthy volunteers and plaque psoriasis patients, not a vaccine; the PPD skin challenge is not a vaccine either. patients true for the psoriasis cohort."
},
{
"nct": "NCT02210780",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dupilumab vs placebo for its effect on vaccine responses; the vaccines are not named in the record."
},
{
"nct": "NCT02212457",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got a meningococcal vaccine (MenABCWY schedules or Bexsero); saline and Havrix only fill schedule slots for blinding."
},
{
"nct": "NCT02218697",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups got QIV and PPV23 within the AE window (together, or PPV23 28 days later); only whole-study groups are reported."
},
{
"nct": "NCT02225587",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups got Prevnar 13 and Pneumovax 23 in different sequences; placebo only fills a schedule slot."
},
{
"nct": "NCT02261961",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests a nutritional supplement vs Kool-Aid placebo; both arms got Tdap."
},
{
"nct": "NCT02269423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V920 (rVSV-ZEBOV) doses pooled; vaccine cohorts also got saline in the other deltoid, the placebo cohort saline in both."
},
{
"nct": "NCT02280408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V920 (rVSV-ZEBOV) doses pooled against saline."
},
{
"nct": "NCT02285777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Extension of a randomized parent study: the MenABCWY group got a third MenABCWY dose, the 'MenACWY Group' only placebo in this study (labelled active comparator for its parent-study MenACWY dose), so parent-study history differs. MenABCWY's MenB component is aluminium-adsorbed."
},
{
"nct": "NCT02287480",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VSV-ZEBOV doses pooled, including the 3x10^5 pfu group added by amendment."
},
{
"nct": "NCT02289820",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "MEDI7510 (RSV sF with GLA-SE)"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "No group got placebo in place of MEDI7510, so the study vaccine has no comparison. In cohorts 2 and 3 participants got MEDI7510 with a marketed inactivated influenza vaccine or with placebo in the other arm: IIV against placebo on a MEDI7510 background, the two GLA doses pooled. EG000 and EG006 (MEDI7510 alone) and EG001 (IIV alone) left out. Target is that of the vaccine compared (IIV); the IIV's brand is not named, taken as unadjuvanted.",
"third_reader_reason": "Coder 1 took the influenza vaccine against placebo on a MEDI7510 background; coder 2 excluded the trial because MEDI7510 itself has no placebo. The cohort 2 and 3 groups differ only in a licensed vaccine given in place of placebo, which the codebook's definitions and note 9 count as a clean comparison, so I side with coder 1."
},
{
"nct": "NCT02297698",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "NeuVax (nelipepimut-S) breast cancer vaccine vs GM-CSF, both with trastuzumab."
},
{
"nct": "NCT02298179",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003",
"EG007",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three dose cohorts, each with its own saline placebo group, and three adjuvant formulations (none, aluminium hydroxide, MF59) pooled."
},
{
"nct": "NCT02301611",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Autologous tumor lysate dendritic cell vaccine against melanoma recurrence: a cancer vaccine."
},
{
"nct": "NCT02302066",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-003 schedules pooled; vaccine groups got placebo at the visits without TDV. Placebo composition not given."
},
{
"nct": "NCT02314923",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V920 doses in both cohorts pooled against both cohorts' saline placebo groups."
},
{
"nct": "NCT02315703",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All seven Ad26 / MVA / gp140 (aluminium phosphate) regimens pooled against saline (Group 8). Groups 1-2's SAE window runs to week 336 through a long-term extension without placebo; other AEs cover the main study (to week 96) for all."
},
{
"nct": "NCT02316470",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA84 arms are labelled active comparator but are vaccine doses; placebo is PBS."
},
{
"nct": "NCT02326805",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "PROSTVAC prostate cancer vaccine."
},
{
"nct": "NCT02340338",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rTSST-1 variant is a recombinant toxoid of S. aureus toxic shock syndrome toxin-1; control is Al(OH)3 adjuvant alone, so the vaccine is taken as aluminium-adjuvanted. Doses pooled."
},
{
"nct": "NCT02344407",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd3-EBO Z and rVSV-ZEBOV against one saline placebo."
},
{
"nct": "NCT02362451",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TARP peptide dendritic-cell vaccine against prostate cancer."
},
{
"nct": "NCT02366728",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV pp65 dendritic-cell vaccine for glioblastoma; Td is given as injection-site preconditioning, controlled by unpulsed DCs, not by placebo."
},
{
"nct": "NCT02374814",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The record says adverse events were collected for 372 days in the four rabies vaccine groups and 7 days in the two placebo (albumin and saline) groups: unequal follow-up, note 18.",
"third_reader_reason": "Coder 1 excluded the trial for unequal follow-up and coder 2 took all four vaccine groups against the two placebo groups. The record gives 7 days of collection for placebo against 372 for vaccine, which note 18 makes ineligible, so I side with coder 1."
},
{
"nct": "NCT02377349",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Mothers crossed over at delivery (control mothers got Boostrix within 72 hours) and each mother group spans both doses, so the mothers' groups are left out (note 7). Infants are compared by their mothers' dose in pregnancy; control infants' mothers were vaccinated after birth. Household group EG004 was not randomized. Boostrix holds aluminium salts; the placebo is named saline.",
"third_reader_reason": "Both coders took only the infants' groups and differed on the placebo: inert for coder 1, not stated for coder 2. The record names the intervention 'Saline placebo', so it is inert and I side with coder 1."
},
{
"nct": "NCT02382913",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Persistence extension; every group got an aP or Tdap booster in the parent study, there is no placebo group, and no AE data were collected."
},
{
"nct": "NCT02383498",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Yeast-brachyury vaccine against chordoma."
},
{
"nct": "NCT02388165",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "SA4Ag holds two capsular polysaccharide conjugates and two recombinant proteins and is unadjuvanted, as published for the product. Placebo is the vaccine's excipients in water. Adults scheduled for spinal fusion surgery.",
"third_reader_reason": "The coders differed on the adjuvant: none for coder 1, unknown for coder 2. The record names SA4Ag, which is published as an unadjuvanted vaccine, so by note 1 I code none and side with coder 1."
},
{
"nct": "NCT02388997",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Omalizumab vs placebo before an experimental rhinovirus challenge; no vaccine."
},
{
"nct": "NCT02396134",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMVPepVax (pp65 peptide) to prevent CMV events after allogeneic HCT, taken as preventive (like a zoster vaccine against reactivation). Adjuvant from the product: given with the TLR9 agonist PF03512676."
},
{
"nct": "NCT02404311",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part A (first randomization): ALVAC-HIV plus gp120/MF59 vs placebos (stabilizer in NaCl, and saline). Part B re-randomized vaccinees at month 30; EG002-EG004 left out."
},
{
"nct": "NCT02414828",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AERAS-402 (adenovirus-vectored TB vaccine) in adults who completed TB treatment, to prevent recurrence; taken as preventive. Placebo is the formulation buffer."
},
{
"nct": "NCT02415166",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Major depression patients and healthy controls pooled; the vaccine serves as an immune challenge. The IM seasonal influenza vaccine is not named; taken as inactivated, unadjuvanted."
},
{
"nct": "NCT02415387",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover typhoid vaccine (as immune stress) vs placebo in breast cancer survivors; AE groups are by product received in either period, each participant in both, with no first-period groups."
},
{
"nct": "NCT02416453",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG006",
"EG008",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.ZEBOV prime with MVA-BN-Filo boost at three intervals (cohorts II-III) and Group 4's Ad26.ZEBOV alone, pooled against their saline placebo groups. Cohort I groups (EG000-EG002) had no placebo arm and are left out."
},
{
"nct": "NCT02438423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TIV by microneedle patch (staff- or self-applied) vs placebo patch; the IM TIV group (EG001) is left out since no placebo was given by injection."
},
{
"nct": "NCT02450578",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DSM265 antimalarial drug before a sporozoite challenge; no vaccine."
},
{
"nct": "NCT02453048",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1 intranasal live attenuated pertussis vaccine; placebo is diluent. Non-randomized PRN-high group EG004 left out."
},
{
"nct": "NCT02459262",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006",
"EG010"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Parts A and B pooled. Part B's placebo is Alhydrogel in buffer; Part A's was Alhydrogel in buffer or buffer alone, recorded as adjuvant."
},
{
"nct": "NCT02465216",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ID93 + GLA-SE in HIV-negative adults after TB treatment completion, to prevent recurrence; taken as preventive. Placebo is saline."
},
{
"nct": "NCT02465268",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV pp65 RNA-pulsed dendritic-cell vaccine for glioblastoma; Td given to all as a booster or skin prep."
},
{
"nct": "NCT02473510",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated trivalent influenza vaccine vs matched placebo."
},
{
"nct": "NCT02485301",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo group got ChAd3-EBO-Z at Month 6, inside the SAE window (to Month 12); only whole-study groups are reported."
},
{
"nct": "NCT02491463",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd155-RSV doses pooled; Bexsero active-control group EG003 left out."
},
{
"nct": "NCT02492958",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two age strata pooled. SA4Ag (two polysaccharide conjugates and two proteins) is unadjuvanted, as published for the product; the placebo is its excipients without the active ingredients.",
"third_reader_reason": "The coders differed on the adjuvant: none for coder 1, unknown for coder 2. SA4Ag is named and is published as unadjuvanted, so by note 1 I code none and side with coder 1."
},
{
"nct": "NCT02496897",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "FP-02.2 therapeutic peptide vaccine for chronic hepatitis B."
},
{
"nct": "NCT02503202",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rVSV-ZEBOV consistency and high-dose lots pooled against saline."
},
{
"nct": "NCT02506933",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV-MVA Triplex in CMV-seropositive HCT recipients to prevent CMV complications, taken as preventive."
},
{
"nct": "NCT02508194",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "inactivated influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo + IIV arm is labelled active comparator, but its control is saline placebo for MEDI7510 (sF with GLA-SE)."
},
{
"nct": "NCT02509494",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Controls got MenACWY (active control) then placebo; Stage 1 had no control."
},
{
"nct": "NCT02519855",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza",
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups got Zostavax and influenza vaccine within the AE window (together, or 4 weeks apart)."
},
{
"nct": "NCT02522949",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ColdZyme mouth spray (device) against induced rhinovirus cold; no vaccine."
},
{
"nct": "NCT02531698",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm got licensed hepatitis A vaccine (months 0, 6) with saline only at month 2: active control."
},
{
"nct": "NCT02531802",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG017",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG019",
"platforms": [
"inactivated",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG009",
"EG014",
"EG020"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ETVAX: formalin-killed E. coli given by mouth (inactivated, note 2) together with 1 mg of the recombinant LCTBA toxin-subunit protein, so both platforms are listed. Groups with dmLT take adjuvant other (note 3). Placebo is the bicarbonate buffer. All four age cohorts pooled.",
"third_reader_reason": "The coders agreed on the groups and adjuvants and differed on the platform: inactivated alone for coder 1, inactivated and protein for coder 2. The record lists the recombinant LCTBA protein as an antigen beside the killed bacteria, and two-component products are coded with both platforms elsewhere, so I side with coder 2."
},
{
"nct": "NCT02534935",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm got pediatric hepatitis A vaccine (months 0, 6) with saline only at month 2: active control."
},
{
"nct": "NCT02538341",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "ongoing anti-TNF therapy"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax vs saline in anti-TNF users with inflammatory disease."
},
{
"nct": "NCT02543892",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-cell inactivated pneumococcal vaccine on aluminium hydroxide; adult and toddler cohorts pooled."
},
{
"nct": "NCT02547974",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: non-typeable Haemophilus influenzae and Moraxella catarrhalis (PD, PE-PilA and UspA2 proteins). F1 is stated unadjuvanted; F2 and F3 are stated adjuvanted without the adjuvant's name, which for GSK's NTHi-Mcat vaccine is AS01E. The saline placebo group pools both steps.",
"third_reader_reason": "The coders differed on the adjuvant of the two adjuvanted formulations: unknown for coder 1, other for coder 2. The record gives the maker's code and says they are adjuvanted, and the published adjuvant of this GSK vaccine is AS01E, which holds no aluminium, so by note 1 I side with coder 2."
},
{
"nct": "NCT02551809",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "UB-311 is an anti-amyloid vaccine for Alzheimer's disease."
},
{
"nct": "NCT02561195",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the first randomization's groups (both schedules, both doses, saline placebo). EG006 to EG013 are the same vaccine recipients randomized again to a fourth dose or placebo, left out. The record does not give the composition; the toxoid vaccine of this programme (100 or 200 mcg total toxoid, day and month regimens) is published as formulated with aluminium hydroxide.",
"third_reader_reason": "The coders agreed on the groups and differed on the adjuvant: unknown for coder 1, aluminium for coder 2. The trial's vaccine is identifiable as the toxoid vaccine whose published formulation in this and the later efficacy trial holds aluminium hydroxide, so by note 1 I side with coder 2."
},
{
"nct": "NCT02562482",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CHIKV virus-like particle vaccine; adjuvant not stated. Placebo is PBS."
},
{
"nct": "NCT02564523",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG014",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009",
"EG011",
"EG013",
"EG015",
"EG017"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Ad26.ZEBOV prime, MVA-BN-Filo boost (both vectors) vs saline. Pooled all intervals and cohorts (healthy adults/elderly, HIV-infected adults, adolescents, children); patients true because cohort 2a enrolled HIV-infected adults. Cohort 1 third dose was also placebo-controlled."
},
{
"nct": "NCT02566265",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both arms get influenza vaccine at day 0 (control arm's is standard of care, standard dose if <65); the trial compares a high-dose booster at day 30 with placebo."
},
{
"nct": "NCT02585700",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split inactivated TIV, no adjuvant mentioned; placebo PBS."
},
{
"nct": "NCT02587221",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Boostrix (Tdap), an active vaccine control despite the Placebo Comparator label."
},
{
"nct": "NCT02598089",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split-virion TIV (IVACFLU-S), no adjuvant mentioned; placebo PBS."
},
{
"nct": "NCT02598388",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MVA-BN-Filo and Ad26.ZEBOV in either order vs saline; pooled both parts, both orders, healthy and HIV-infected participants (patients true for the HIV-infected groups)."
},
{
"nct": "NCT02612909",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-virion inactivated H5N1 vaccine, stated as formulated with aluminium hydroxide 0.6 mg per dose. Phase 2 and phase 3 parts pooled. Placebo is phosphate-buffered saline.",
"third_reader_reason": "The coders differed on the adjuvant: aluminium for coder 1, none for coder 2. The intervention's description says the vaccine is formulated with aluminium hydroxide, so I side with coder 1."
},
{
"nct": "NCT02623725",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "prior 3-dose CYD-TDV series in earlier trials"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV booster vs saline in people who completed 3 doses in earlier studies."
},
{
"nct": "NCT02624947",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal RSV F nanoparticle vaccine with aluminium phosphate vs formulation buffer; infants as second comparison."
},
{
"nct": "NCT02628444",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage I groups all receive CYD (1, 2 or 3 doses, placebo in place of earlier doses); groups cover the whole period, so no placebo-only group; stage II is booster only."
},
{
"nct": "NCT02640716",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Cognitive training program (named 'Cog-VACCINE'); no vaccine."
},
{
"nct": "NCT02642237",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get Fluenz; the trial tests IV LPS vs placebo before it."
},
{
"nct": "NCT02646371",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flexyn2a is an O-polysaccharide bioconjugate against Shigella flexneri 2a. The record does not say whether it was given with an adjuvant, and the product has been tested both ways, so adjuvant unknown. Placebo is Tris-buffered saline. The groups are those of the vaccination phase, before the challenge.",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, none for coder 2 because the record names none. A conjugate is not a platform that carries no adjuvant and the record is silent, so it is not stated and not known with confidence: unknown, with coder 1."
},
{
"nct": "NCT02646891",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "P2-VP8 subunit on aluminium hydroxide vs saline; adult, toddler and infant cohorts pooled."
},
{
"nct": "NCT02649192",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get Fluzone; the trial tests vitamin A and D supplements vs placebo."
},
{
"nct": "NCT02660489",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "OC459 (CRTH2 antagonist drug) with rhinovirus challenge in asthma; no vaccine."
},
{
"nct": "NCT02661490",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets the norovirus VLP vaccine (1-dose arms get placebo then vaccine on day 29); compares formulations and schedules."
},
{
"nct": "NCT02669121",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent norovirus VLP with aluminium hydroxide vs saline."
},
{
"nct": "NCT02678455",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TV005 live attenuated tetravalent dengue vaccine; placebo composition not given."
},
{
"nct": "NCT02707692",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Three-period crossover (Pneumovax, Fluarix, saline in randomized orders) given to perturb the HIV reservoir; AE groups are by product across periods, so each participant appears in all three and no first-period groups are reported."
},
{
"nct": "NCT02708745",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral survey intervention about vaccine hesitancy; no vaccine given."
},
{
"nct": "NCT02712424",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DAR-901 is published as a heat-inactivated whole-cell non-tuberculous mycobacterium given as a tuberculosis booster, with no adjuvant; the record names the product but not its composition. Prior BCG was an entry criterion, not something given in the trial. Placebo is sterile saline.",
"third_reader_reason": "Coder 1 gave platform other and adjuvant unknown because the record does not describe DAR-901; coder 2 gave inactivated and none. The record names the product and its composition is published, so by note 1 I code it as a killed whole-cell vaccine without adjuvant and side with coder 2."
},
{
"nct": "NCT02717494",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Step 1 groups only: PPV-23 (plain) and PCV-10 (licensed in Brazil, Synflorix, aluminium phosphate) vs saline in HIV-infected pregnant women; infants as second comparison. Left out EG003/EG004: placebo recipients vaccinated postpartum (step 2)."
},
{
"nct": "NCT02726178",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "All preterm infants get their primary immunizations; the trial tests ibuprofen vs placebo around them. Vaccines not named."
},
{
"nct": "NCT02738450",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACI-24 is an anti-amyloid vaccine (Alzheimer's prevention in Down syndrome), a non-infectious target."
},
{
"nct": "NCT02741128",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CYD-TDV vs saline in HIV-positive adults."
},
{
"nct": "NCT02743117",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent intranasal cold-adapted live attenuated influenza vaccine; placebo composition not given."
},
{
"nct": "NCT02747927",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tables report the same participants again by Part (1-5). Took Part 1 (EG000/EG001: vaccination period, the only part with all AEs); left out Parts 2-3 (later follow-up of the same participants; Part 3 is longer, about 3 years, but SAEs only) and Parts 4-5 (booster subset). Placebo composition not given."
},
{
"nct": "NCT02750202",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Quadrivalent HPV vaccine given to people with genital warts to prevent recurrence; control is hepatitis B vaccine (active control)."
},
{
"nct": "NCT02756208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IHV01 is the full-length single-chain gp120-CD4 protein, published as formulated in aluminium phosphate; the record does not state the adjuvant. HIV-uninfected adults. Placebo is sterile saline.",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, aluminium for coder 2. The record names IHV01, whose published formulation is in aluminium phosphate, so by note 1 I side with coder 2."
},
{
"nct": "NCT02788045",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26 mosaic vectors (weeks 0, 12) then Ad26 plus clade C gp140 with aluminium phosphate (weeks 24, 48) vs pooled saline placebo."
},
{
"nct": "NCT02788188",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SAB-301 is a polyclonal antibody against MERS-CoV, not a vaccine."
},
{
"nct": "NCT02794870",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSV LID dM2-2 1030s vs isotonic diluent in seronegative children."
},
{
"nct": "NCT02807623",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets influenza vaccine; the trial tests ibuprofen, placebo, or push-ups after it."
},
{
"nct": "NCT02810340",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Menactra, an active vaccine."
},
{
"nct": "NCT02814643",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both arms get seasonal influenza vaccine; the trial tests benralizumab vs placebo."
},
{
"nct": "NCT02814708",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Recombinant TSST-1 variant toxoid against staphylococcal toxic shock; control got Al(OH)3 adjuvant alone, so the vaccine's adjuvant is taken as aluminium. Groups with 1 or 2 immunizations got adjuvant for the remaining injections. All doses pooled."
},
{
"nct": "NCT02824198",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "prior 3-dose CYD-TDV series in an earlier trial"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV booster vs saline in people who completed 3 doses in CYD28."
},
{
"nct": "NCT02826798",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CMV gB enveloped VLP, with Adju-Phos (aluminium phosphate) or without; placebo buffer/sucrose."
},
{
"nct": "NCT02839161",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Hookworm vaccines (Na-APR-1, Na-GST-1); control is hepatitis B vaccine plus saline, an active control. Target other: hookworm."
},
{
"nct": "NCT02839330",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cell-derived H5N1 subunit vaccine with MF59 (three lots pooled in EG000) vs saline."
},
{
"nct": "NCT02852005",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "MVA/HIV62B at months 0 and 4"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AIDSVAX B/E against saline in the other arm, both sides given MVA/HIV62B; the two strata by earlier regimen (groups 2 against 1, groups 4 against 3) pooled. EG004 (placebo with AIDSVAX) left out: its partner for MVA against placebo, EG003, is already used (note 4). AIDSVAX B/E is gp120 on aluminium hydroxide, as known for the product. All were vaccinated before in HVTN 205.",
"third_reader_reason": "Coder 1 took AIDSVAX against saline on an MVA background; coder 2 excluded the trial because every arm gets a vaccine. Groups 2 and 4 differ from groups 1 and 3 only in AIDSVAX in place of saline, a clean comparison with a shared co-administered vaccine, so I take coder 1's groups; I differ from coder 1 only in coding the adjuvant aluminium, which is known for AIDSVAX B/E."
},
{
"nct": "NCT02861586",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every MV-CHIK group gets MV-CHIK within the AE period (placebo only replaces some doses); controls are Priorix, an active vaccine."
},
{
"nct": "NCT02873286",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA-BN-RSV against Tris-buffered saline. Took the two-dose groups, followed 30 weeks like placebo. EG000 and EG002 left out: those groups include a week-56 booster with no placebo and follow-up to 108 weeks for those who took part in it, against 30 weeks for placebo (note 18).",
"third_reader_reason": "Coder 1 took only the two-dose groups; coder 2 took all four vaccine groups. Groups 1 and 3 run through an uncontrolled booster to 108 weeks while placebo was followed 30 weeks, so by the codebook's placebo-controlled-period rule and note 18 I leave them out and side with coder 1; the two-dose groups remain a clean comparison."
},
{
"nct": "NCT02876328",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG014",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG015",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG005",
"EG009",
"EG013",
"EG017",
"EG019"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PREVAC: Ad26.ZEBOV/MVA-BN-Filo and rVSV-ZEBOV regimens vs saline; adults and children under protocol versions 2.0-4.0 pooled."
},
{
"nct": "NCT02888756",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "iHIVARNA-01 is a therapeutic mRNA vaccine for chronically HIV-infected people on ART."
},
{
"nct": "NCT02890381",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSV LID cp dM2-2 vs isotonic diluent in seronegative children."
},
{
"nct": "NCT02894840",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split-virion TIV, no adjuvant mentioned; phase I and II groups pooled; placebo composition not given."
},
{
"nct": "NCT02915016",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIV DNA plus gp120 with MF59 or AS01B (groups 1-6) and gp120/AS01B alone (group 7), each vs the saline-only group 8."
},
{
"nct": "NCT02918006",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "H1N1 influenza challenge after vaccination"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Double-dummy design: oral Ad5 vector tablets with dsRNA adjuvant plus saline injection, Fluzone Quadrivalent plus placebo tablets, or both placebos. Each active group differs from the placebo group only in its vaccine. Placebo tablets' composition is not given (note 8). The only groups span the challenge given to all.",
"third_reader_reason": "Coder 1 took both the oral vaccine and the Fluzone group as vaccine groups; coder 2 left Fluzone out as an active control. With matching oral and injected placebos the Fluzone group differs from the placebo group only in a licensed vaccine, which note 9 makes a vaccine group, so I side with coder 1."
},
{
"nct": "NCT02919306",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccine (Ad26/MVA mosaic) in HIV-infected adults on ART."
},
{
"nct": "NCT02925403",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only two AE groups reported: EG001 is titled 'Group 2' but its description is the saline arm, so taken as placebo; the 50 ug arm has no AE group. R21/Matrix-M1: protein, Matrix-M adjuvant."
},
{
"nct": "NCT02927873",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG004",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd155-RSV doses pooled against the three volume-matched placebo groups."
},
{
"nct": "NCT02934178",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only cohort 1 (3x10^3 CFU) and its placebo are reported as AE groups. Oral live attenuated Shigella sonnei WRSS1; placebo sterile saline."
},
{
"nct": "NCT02935192",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split inactivated TIV, composition given without adjuvant; placebo PBS."
},
{
"nct": "NCT02935686",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "First randomization taken (Groups 1-2 vs Group 3 main study). EG003/EG004 left out: a later re-randomization of vaccine recipients to late boost or placebo. Vaccine groups also include LTE follow-up (to Week 216) while placebo runs to Week 72."
},
{
"nct": "NCT02942277",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Comparator arms received Engerix-B (and Menactra), an active control vaccine; saline was only a diluent/dose filler."
},
{
"nct": "NCT02948959",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dupilumab (monoclonal antibody) for asthma; no vaccine."
},
{
"nct": "NCT02956746",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests SYN023 antibody vs human rabies immune globulin; every arm gets rabies vaccine (vaccine_in_every_arm also applies)."
},
{
"nct": "NCT02956837",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK3003891A dosed in ug of antigen (protein); adjuvant not stated. Placebo is formulation buffer S9b. Non-pregnant healthy women."
},
{
"nct": "NCT02958345",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax in adults with cirrhosis; placebo normal saline."
},
{
"nct": "NCT02962908",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two comparisons because vaccine and placebo divide together (note 5): unadjuvanted FLU-v twice against saline twice, and Montanide ISA-51 FLU-v then saline against Montanide alone then saline. FLU-v is a mix of synthetic peptides, as published for the product.",
"third_reader_reason": "The coders agreed on the two comparisons and differed on the platform: other for coder 1 because the record does not describe FLU-v, protein for coder 2. The record names FLU-v, which is published as a synthetic peptide vaccine, and peptides are coded protein, so by note 1 I side with coder 2."
},
{
"nct": "NCT02968849",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV plus bivalent gp120/MF59 vs sodium chloride."
},
{
"nct": "NCT02971670",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Booster amendment of a Phase I trial: participants re-immunized by their former allocation (vaccine dose or placebo), so the placebo control carries over from the Phase I allocation; the registry does not list this record as randomized. Control is Al(OH)3 adjuvant alone. Recombinant TSST-1 toxoid variant against staphylococcal toxic shock. AE time frame not given."
},
{
"nct": "NCT02978222",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Folate receptor alpha peptide cancer vaccine in ovarian cancer; control GM-CSF alone."
},
{
"nct": "NCT02992197",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Single vs double Rotarix inoculum; both arms get Rotarix."
},
{
"nct": "NCT02998996",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal influenza antigen with 1% or 2% Endocine, or alone, against intranasal saline. Immunose FLU is described by its maker as split influenza antigen with the Endocine adjuvant; the record says only 15 mcg HA per strain. EG004 and EG005 (intramuscular and intranasal comparators) left out: unblinded comparators with a shorter schedule and no placebo given in their place.",
"third_reader_reason": "The coders agreed on the groups and adjuvants and differed on the platform: other for coder 1 because the record does not say split or subunit, inactivated for coder 2. The record names Immunose FLU, which its maker describes as split antigen with Endocine, so by note 1 I code inactivated and side with coder 2."
},
{
"nct": "NCT03008122",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ZPIV with aluminium hydroxide; placebo composition not given. Flavivirus-endemic area, healthy adults."
},
{
"nct": "NCT03012100",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Folate receptor alpha peptide cancer vaccine in triple negative breast cancer."
},
{
"nct": "NCT03014089",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Group titles and descriptions disagree: titles run 10 mcg, 25 mcg, 100 mcg, Placebo; descriptions run 10 mcg, placebo, 25 mcg, 100 mcg. Went by the descriptions (note 15), which name one placebo group, EG001. Placebo is 0.9% sodium chloride.",
"third_reader_reason": "Coder 1 excluded the trial because titles and descriptions conflict on which group got placebo; coder 2 went by the titles and took EG003 as placebo. Note 15 says to go by the descriptions, and they name exactly one placebo group, EG001, so I side with neither: eligible, with EG001 as placebo."
},
{
"nct": "NCT03014622",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DaxibotulinumtoxinA for glabellar lines; no vaccine."
},
{
"nct": "NCT03014635",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DaxibotulinumtoxinA for glabellar lines; no vaccine."
},
{
"nct": "NCT03018288",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HSPPC-96 autologous tumor vaccine in glioblastoma."
},
{
"nct": "NCT03031912",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V920 (rVSV-ZEBOV) in HIV-infected adults and adolescents; CD4 cohorts pooled. Placebo normal saline."
},
{
"nct": "NCT03040687",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral bovine serum immunoglobulin (passive antibody) against ETEC challenge; no vaccine."
},
{
"nct": "NCT03051516",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Gardasil 9 given as therapy to interrupt progression of existing high-grade vulvar or anal lesions (HPV-lesion use)."
},
{
"nct": "NCT03055000",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': mosquito-borne diseases in general (AGS-v, mosquito saliva peptides). Adjuvanted arm uses Montanide ISA-51. Placebo water for injection."
},
{
"nct": "NCT03058692",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal quadrivalent influenza vaccine on Day 172"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M-001 recombinant epitope protein, adjuvant not stated. Both arms get IIV4 on Day 172; placebo saline."
},
{
"nct": "NCT03060629",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.Mos4.HIV plus aluminium phosphate-adjuvanted clade C gp140; 'matching placebo' composition not given."
},
{
"nct": "NCT03073525",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Vigil autologous tumor cell immunotherapy with atezolizumab in gynecological cancers."
},
{
"nct": "NCT03090191",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid-based C. difficile vaccine, 200 mcg total toxoid at months 0, 1 and 6, against normal saline. The record does not state the adjuvant; this efficacy trial's vaccine is published as formulated with aluminium hydroxide.",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, aluminium for coder 2. The trial's toxoid vaccine is identifiable and its published formulation holds aluminium hydroxide, so by note 1 I side with coder 2."
},
{
"nct": "NCT03092791",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only the adult lead-in cohort is placebo-controlled (EG000 vs EG001). Toddler and infant cohorts (EG002-EG007) left out: control is reference IPV. sIPV adjuvant not stated."
},
{
"nct": "NCT03095599",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IVACFLU-S split TIV, composition given without adjuvant; placebo PBS."
},
{
"nct": "NCT03101111",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm received MMR vaccine (active control); saline was only a dummy injection in both arms."
},
{
"nct": "NCT03101267",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP4070, an allergy vaccine for cedar pollinosis."
},
{
"nct": "NCT03102034",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSV in seronegative infants; placebo isotonic diluent."
},
{
"nct": "NCT03110770",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Part B was randomized against placebo (Group 4 vs Group 5); Part A groups EG000-EG002 left out (no placebo in Part A). Placebo PBS."
},
{
"nct": "NCT03122223",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV plus gp120 with MF59 (EG000) or AS01B (EG001, EG002) vs sodium chloride."
},
{
"nct": "NCT03135834",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY vs licensed rLP2086 + MenACWY-CRM (active control); saline only balances injections."
},
{
"nct": "NCT03143218",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RTS,S/AS01 has no placebo: the SMC-alone arm received rabies and hepatitis A vaccines as control vaccines; placebo was given only for SMC drugs."
},
{
"nct": "NCT03146403",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"herpes_simplex"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GEN-003 therapeutic HSV-2 vaccine (maintenance dose) in people with genital herpes."
},
{
"nct": "NCT03158038",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent cold-adapted LAIV intranasal; matching placebo composition not given."
},
{
"nct": "NCT03170609",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GBS6 is a six-valent capsular polysaccharide conjugate, as published for the product. Adjuvant by group: with or without aluminium phosphate, as the group titles say. Placebo is saline.",
"third_reader_reason": "The coders agreed on the groups and adjuvants and differed on the platform: other for coder 1 because the record calls it only a multivalent GBS vaccine, polysaccharide for coder 2. The groups name GBS6, published as a polysaccharide conjugate, so by note 1 I side with coder 2."
},
{
"nct": "NCT03172975",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "controlled human hookworm infection on Day 140, albendazole at end"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': hookworm (Necator americanus). EG001/EG002 add CpG 10104 or GLA-AF as co-administered adjuvants (TLR agonists), treated as vaccine formulations, all with Alhydrogel. Placebo saline."
},
{
"nct": "NCT03180801",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Adverse events run from the first dose to the challenge, so the groups are before the challenge. Placebo is the Montanide ISA-51 emulsion without antigen. FLU-v is a mix of synthetic peptides, as published for the product.",
"third_reader_reason": "The coders differed only on the platform: other for coder 1 because the record does not describe FLU-v, protein for coder 2. FLU-v is named and is published as a synthetic peptide vaccine, so by note 1 I code protein and side with coder 2."
},
{
"nct": "NCT03181789",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "electroporation delivery in both arms"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIV gag pDNA vaccines with IL-12 pDNA, which the record calls the adjuvant, coded as adjuvant 'other' rather than a separate immune modulator. Both control groups saline by electroporation."
},
{
"nct": "NCT03201211",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Long-term follow-up (Month 20 to 50, SAEs only, no vaccine given) of the parent study's randomized arms: AS01E-adjuvanted NTHi-Mcat protein vaccine (two formulations, pooled) vs saline; no crossover reported. Target other: non-typeable Haemophilus influenzae and Moraxella catarrhalis."
},
{
"nct": "NCT03220737",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vaxchora (CVD 103-HgR) in children; age cohorts pooled; placebo saline. Historical adult control has no AE group. AE groups are the safety population as treated."
},
{
"nct": "NCT03227029",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two intranasal live attenuated RSV candidates vs isotonic diluent."
},
{
"nct": "NCT03275389",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm is Fluarix Quadrivalent (active); placebo only fills a Day 57 dose slot, and AE groups are not split by dose."
},
{
"nct": "NCT03281876",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target other: non-typeable Haemophilus influenzae and Moraxella catarrhalis, to reduce COPD exacerbations. The record says the vaccine is adjuvanted without naming the adjuvant, which for GSK3277511A is AS01E. Enrolled COPD patients, though the arm text says healthy.",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, other for coder 2. The record gives the maker's code and says the vaccine is adjuvanted, and its published adjuvant is AS01E, with no aluminium, so by note 1 I side with coder 2."
},
{
"nct": "NCT03284710",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All four arms get ALVAC-HIV plus gp120 (MF59, alum, or none, different schedules); no placebo group."
},
{
"nct": "NCT03284866",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Gardasil 9 given as 'HPV vaccine therapy' to reduce high-grade cervical lesions in HIV-infected women with HPV in a test-and-treat program (HPV-lesion use)."
},
{
"nct": "NCT03293498",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "NanoFlu vs Fluzone HD on Day 0 (active control); saline only fills Day 21 in the control arm."
},
{
"nct": "NCT03295318",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "NmCV-5 formulations vs Menactra (active control)."
},
{
"nct": "NCT03300050",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated",
"live_attenuated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated",
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two schedules, each with a route-matched inert placebo (intranasal saline then PBS injection; PBS injection twice), pooled as one design since neither side has a background. AS03 is in the second dose of EG000 and both doses of EG003.",
"third_reader_reason": "Coder 1 pooled the two schedules into one comparison; coder 2 made two, one per placebo route. The codebook separates comparisons only when the background differs or for offspring, and both placebos are inert with no background, so I pool and side with coder 1."
},
{
"nct": "NCT03301051",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Plant-derived quadrivalent virus-like-particle influenza vaccine, published as unadjuvanted. EG000's description says 'vaccine or placebo', read as a slip: its title and the arm say vaccine, and EG001 is the placebo group by title and description. Placebo's composition is not given.",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, none for coder 2. The plant-derived quadrivalent VLP influenza vaccine is published as unadjuvanted, and the codebook codes unadjuvanted influenza vaccine none, so I side with coder 2."
},
{
"nct": "NCT03303625",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF; adult and toddler cohorts pooled."
},
{
"nct": "NCT03312231",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H7N9 doses with or without AS03; no placebo arm."
},
{
"nct": "NCT03313037",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC then saline vs 13vPnC then PPSV23 (active control)."
},
{
"nct": "NCT03318315",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label; the IIV4-only group got no placebo in place of the H7N9 vaccine."
},
{
"nct": "NCT03325075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The tables report the same participants after vaccination 1, after vaccination 2 and in Part B's later follow-up; no group spans the whole follow-up, so took the vaccination 1 groups, which begin at the first dose and count each participant once (note 6). VAL-181388 is an mRNA vaccine, as published for the maker's code. Placebo is saline.",
"third_reader_reason": "Both coders took the Part B follow-up groups and differed on the platform: other for coder 1, mRNA for coder 2. Note 6 says to take the groups that begin at the first vaccination, here those after the first dose, so I side with neither on the groups; on the platform I agree with coder 2, since the maker's code names a published mRNA vaccine."
},
{
"nct": "NCT03334695",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the post-dose groups, before the challenge (note 6). EG002 and EG003 report the same participants after an RSV challenge given to all, left out. Placebo is 0.9% saline.",
"third_reader_reason": "Coder 1 took the post-dose groups and coder 2 the post-challenge groups as the longer follow-up. Note 6 says a challenge trial takes the groups before the challenge, so I side with coder 1."
},
{
"nct": "NCT03339713",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal influenza vaccine (Fluarix)"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the post-dose 1 groups (Ad26.RSV.preF + Fluarix vs placebo + Fluarix); left out post-dose 2 groups after crossover."
},
{
"nct": "NCT03341637",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03342898",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue",
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets TDV and YF-17D in different sequences; groups cover the whole study, placebo only fills a slot."
},
{
"nct": "NCT03343626",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flavivirus-naive and -primed cohorts pooled."
},
{
"nct": "NCT03376477",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "lenalidomide and GM-CSF myeloma cell vaccine"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Prevnar13 vs saline placebo Prevnar, both arms on lenalidomide + GVAX (Arm A vs Arm B). Arm C (EG001) left out: it also lacks GVAX, so differs by more than the vaccine."
},
{
"nct": "NCT03382418",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03387137",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Seropositive and seronegative cohorts pooled; placebo nose drops of unstated composition."
},
{
"nct": "NCT03408262",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "CN54gp140/MPLA at months 3 and 6"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets the CN54gp140/MPLA protein. Group A gets oral and injected placebo in place of the vector vaccines the others get: Ad4-EnvCN54 (groups B to D), MVA-CN54 (group E) or both (groups F to H). Both are vectors carrying HIV envelope, with no adjuvant of their own. The placebos' composition is not given.",
"third_reader_reason": "Coder 1 took groups B to H against group A on a CN54gp140/MPLA background; coder 2 excluded the trial because every arm gets that protein. Group A differs from each other group only in placebo given in place of the vector vaccines, with the protein as a shared co-administered vaccine, which the codebook counts as a clean comparison, so I side with coder 1."
},
{
"nct": "NCT03409276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A (protein/GLA-SE) and Part B (DNA and protein/GLA-SE) pooled, each with its own saline placebo; GLA-SE is a non-aluminium adjuvant."
},
{
"nct": "NCT03423173",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three TDV lots pooled."
},
{
"nct": "NCT03443427",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get three doses of the NTHi-Mcat vaccine on different schedules; placebo only fills the fourth slot. Target other: non-typeable H. influenzae and Moraxella catarrhalis."
},
{
"nct": "NCT03450915",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M-001 (Multimeric-001) is a recombinant multi-epitope protein, given in this trial without adjuvant as published for the product; the record does not state it. Placebo is 0.9% saline.",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, none for coder 2. The record names M-001, whose late-stage formulation is published as unadjuvanted, so by note 1 I side with coder 2."
},
{
"nct": "NCT03461276",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ABvac40 is an anti-amyloid vaccine for Alzheimer's disease."
},
{
"nct": "NCT03483116",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get three RV3-BB doses (neonatal or infant schedule) with placebo in the remaining slot; it compares doses and schedules."
},
{
"nct": "NCT03483961",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All ten groups get CHIKV VLP (doses, adjuvant, schedules); placebo only fills slots."
},
{
"nct": "NCT03486834",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "3-dose and 2-dose V160 pooled. Platform other: V160 is a whole-virus CMV vaccine (replication-defective), not clearly live attenuated or inactivated from the record; adjuvant MAPA (aluminium phosphate)."
},
{
"nct": "NCT03491553",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Selgantolimod is an oral TLR8 agonist for chronic hepatitis B, not a vaccine."
},
{
"nct": "NCT03500679",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ExPEC4V (JNJ-63871860) is a four-valent E. coli O-antigen bioconjugate, published as given without adjuvant; the record does not state it. Placebo is 'matching' with no composition given (note 8).",
"third_reader_reason": "The coders differed on the adjuvant: unknown for coder 1, none for coder 2. The record gives the product and the maker's code, and ExPEC4V is published as an unadjuvanted bioconjugate, so by note 1 I side with coder 2."
},
{
"nct": "NCT03503058",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "weekly chloroquine chemoprophylaxis"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two comparisons: PfSPZ Vaccine vs saline; PfSPZ-CVac (infectious PfSPZ Challenge under chloroquine) vs saline, both with weekly chloroquine. Both are live sporozoites given as the vaccine against malaria: live_attenuated.",
"third_reader_reason": "The coders differed only in the platform of PfSPZ Vaccine (other or live_attenuated) and agreed on other for PfSPZ-CVac. Note 2 makes a live organism given as the vaccine against itself live_attenuated even when it is not attenuated or cannot replicate, so both groups are live_attenuated: coder 2 on the first, neither on the second."
},
{
"nct": "NCT03510481",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before doses 3 and 4"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two dosing schedules pooled, each with its saline control. Radiation-attenuated sporozoites: live_attenuated.",
"third_reader_reason": "The coders differed only in platform (other or live_attenuated). Note 2 names radiation-attenuated sporozoites as live_attenuated, as coder 2 had it."
},
{
"nct": "NCT03512249",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Given to prevent TB recurrence in adults successfully treated for pulmonary TB, taken as preventive; IC31 (KLK + ODN1a) is a non-aluminium adjuvant."
},
{
"nct": "NCT03518125",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"anthrax"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BioThrax vs AV7909 regimens; saline only fills a skipped dose."
},
{
"nct": "NCT03520959",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMB305 is a NY-ESO-1 cancer vaccine for synovial sarcoma."
},
{
"nct": "NCT03525119",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "hepatitis A vaccine on Day 1"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDV+HAV/TDV (EG002) vs HAV+placebo/placebo (EG000). EG001 (TDV + HAV placebo) left out: no group got placebo without HAV vaccine.",
"third_reader_reason": "The coders took different comparisons: TDV against its saline placebo on a hepatitis A vaccine background (coder 1), or hepatitis A vaccine against its placebo on a TDV background (coder 2). EG002 could serve in either, and note 4 takes the one that tests the study vaccine the title names, the dengue vaccine, so coder 1's."
},
{
"nct": "NCT03527173",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "oral S. sonnei 53G challenge at Day 57"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-arm groups, which begin at the first vaccination and run through the challenge both arms got; no pre-challenge groups are reported. 1790GAHB is GMMA (outer-membrane vesicles) adsorbed on aluminium hydroxide. Placebo (GAHB-Placebo) composition not given in the record.",
"third_reader_reason": "The coders agreed on platform other and differed in adjuvant (unknown or aluminium). Note 2 puts outer-membrane vesicles under protein, and 1790GAHB, which the record names by its maker's code, is published as GMMA adsorbed on aluminium hydroxide, so protein with aluminium: coder 2's adjuvant, neither's platform."
},
{
"nct": "NCT03529773",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG013"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG021",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG022",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG023",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG024",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG025",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG026",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG027",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG029",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG030",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG031",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG032",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG020",
"EG039"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal inactivated influenza vaccine at Day 35"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Sentinel cohort (RSV vaccine with or without Al(OH)3 vs placebo) and expanded cohort (RSV vaccine + placebo on Day 1, SIIV on Day 35, vs placebo + placebo, SIIV on Day 35) as two comparisons, ages pooled. Left out the expanded groups given SIIV with the RSV vaccine on Day 1 (EG014-EG019, EG033-EG038): no placebo group got SIIV on Day 1. EG028 left out with them: its title puts it in the Day 35 set but its description gives SIIV on Day 1, and descriptions govern. The record's one placebo is called saline control.",
"third_reader_reason": "The coders differed in the sentinel comparison's placebo content (inert or not_stated): the record's single placebo intervention is described as saline control in the expanded groups, so inert, as coder 1 had it. Both took EG028 by its title, but its description gives SIIV on Day 1 and note 15 goes by descriptions, so I left it out with the other Day 1 SIIV groups."
},
{
"nct": "NCT03541499",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1 at two doses by VaxINator and at 10^9 CFU by syringe, all against the one placebo (the vaccine's excipients without the bacteria). Target is pertussis.",
"third_reader_reason": "The coders differed on EG002, BPZE1 given by needleless syringe: left out by coder 1 because its delivery differs from the placebo's, included by coder 2. It is an arm of the same vaccine against the same placebo, and the codebook counts any dose, formulation or schedule as a vaccine group, so a different intranasal device is no reason to leave it out."
},
{
"nct": "NCT03548064",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG005",
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "dmLT (detoxified ETEC heat-labile toxin) given as the ETEC antigen; oral, sublingual and intradermal routes pooled, each with its own placebo; no separate adjuvant."
},
{
"nct": "NCT03553940",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed quadrivalent inactivated influenza vaccine at Day 92"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication (M2-deficient) influenza virus the record calls live attenuated."
},
{
"nct": "NCT03560258",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV DNA vaccine in people with HIV, virally suppressed on antiretroviral therapy.",
"third_reader_reason": "The coders differed on eligibility. The official title calls it therapeutic vaccination in HIV-infected persons on antiretroviral therapy, which the codebook and note 10 exclude as not preventive, as coder 1 decided."
},
{
"nct": "NCT03562377",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"meningococcal",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests tralokinumab's effect on responses to Tdap and meningococcal vaccines that every arm receives."
},
{
"nct": "NCT03564444",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03572062",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "seasonal inactivated influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Primary cohort (RSVpreF with Al(OH)3, CpG/Al(OH)3 or none, all with SIIV) vs placebo + SIIV; month-0/month-2 cohort (CpG/Al(OH)3, no SIIV) vs placebo as a second comparison. CpG/Al(OH)3 counted as aluminium."
},
{
"nct": "NCT03576183",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "oral ETEC challenge"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-arm groups, which begin at vaccination and include the ETEC challenge both arms got. VLA1701 is Valneva's oral candidate derived from its killed whole-cell cholera vaccine: inactivated; adjuvant not stated. Placebo is the vaccine's buffer.",
"third_reader_reason": "The coders differed in platform (other or inactivated) and targets (cholera with ETEC, or ETEC alone). VLA1701 is derived from a killed whole-cell oral cholera vaccine, so inactivated, and by note 12 the target is the disease the trial gave it to prevent, ETEC, as coder 2 had both."
},
{
"nct": "NCT03579459",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid vaccine, three lots pooled in the tables. Aluminium hydroxide from product knowledge: the 200 mcg toxoid dose at months 0, 1 and 6 is the phase 3 formulation of Pfizer's candidate.",
"third_reader_reason": "The coders differed only in adjuvant (unknown or aluminium). The record does not state it, but the dose and schedule identify the phase 3 toxoid candidate, whose formulation holds aluminium hydroxide, so aluminium, as coder 2 had it."
},
{
"nct": "NCT03583606",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "ChAd3-EBO-Z prime on Day 1"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets ChAd3-EBO-Z on Day 1; took MVA-BN-Filo vs saline on Day 8 (EG002 vs EG000). EG001 left out: a second dose of the vaccine the placebo group also got is a dose comparison.",
"third_reader_reason": "The coders differed on eligibility: MVA-BN-Filo against saline after a ChAd3-EBO-Z prime in both (coder 1), or vaccine in every arm (coder 2). EG002 was randomized to a vaccine, MVA-BN-Filo, that EG000 did not get, with saline in its place and the same prime, which is a clean comparison on a shared background."
},
{
"nct": "NCT03589807",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get H7N9 vaccine; compares strains, intervals and adjuvant."
},
{
"nct": "NCT03596801",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two live-attenuated RSV candidates in seropositive and seronegative cohorts pooled; placebo nose drops of unstated composition."
},
{
"nct": "NCT03606213",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV DNA vaccine with IL-12 plasmid in people with HIV on ART."
},
{
"nct": "NCT03606512",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF vs saline placebo. Left out EG001 (placebo-arm toddlers given Nimenrix on Day 57, an active vaccine the vaccine arm didn't get)."
},
{
"nct": "NCT03610581",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic Ad26/MVA HPV vaccine for women with existing cervical HPV16/18 infection."
},
{
"nct": "NCT03611946",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Chimeric live-attenuated Zika (on DEN4delta30); two dose cohorts pooled."
},
{
"nct": "NCT03615482",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get V114 and QIV, together or 30 days apart; groups cover the whole study."
},
{
"nct": "NCT03621670",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "routine infant vaccines (PCV13/PCV20, Pediarix, Hiberix, Rotarix, MMR, varicella)"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03629080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "kidney transplant with pre-emptive CMV management"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "kidney transplant with 3-6 months antiviral prophylaxis"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pre-emptive and prophylactic management strata kept as separate comparisons (background care differs). Left out EG004/EG005, CMV-seropositive patients given HB-101 with no placebo. HB-101 is replication-deficient rLCMV vectors."
},
{
"nct": "NCT03629886",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Follow-up of HPV-039: women vaccinated before get nothing now; former placebo recipients get the vaccine. No placebo given in this study, and the groups were set by the earlier trial."
},
{
"nct": "NCT03635086",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get MV-CHIK (formulations, doses, one or two doses)."
},
{
"nct": "NCT03636906",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "licensed meningococcal or pneumococcal comparator vaccines"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled randomized groups: one or two doses of ChAd155-RSV vs placebo. Both sides got the same licensed comparator vaccines over the period, at different visits (the control group's first comparator dose could fall on Day 1). Tables are cumulative over all vaccinations.",
"third_reader_reason": "The coders differed on eligibility. Over the period the tables cover, the control group got the same comparator vaccines as the RSV groups and placebo in place of the ChAd155-RSV doses, so the groups differ only in the RSV vaccine; the comparators are a shared background given at shifted visits, not an active control in place of the vaccine, so eligible as coder 2 decided."
},
{
"nct": "NCT03658629",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets an influenza vaccine (Quad-NIV formulations or licensed comparators); placebo only fills Day 28."
},
{
"nct": "NCT03674177",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Unadjuvanted RSV maternal vaccine (by its title) given to non-pregnant women; three doses pooled."
},
{
"nct": "NCT03676764",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Mass or targeted azithromycin vs placebo; no vaccine is tested."
},
{
"nct": "NCT03682107",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: Andes hantavirus (hantavirus pulmonary syndrome). Doses and 3- or 4-dose regimens pooled against pooled saline placebo; vaccine groups include one open-label sentinel each."
},
{
"nct": "NCT03682120",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get H7N9 vaccine (doses, with or without MF59); no placebo arm."
},
{
"nct": "NCT03707041",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "P218 is an antimalarial drug tested against PfSPZ Challenge; no vaccine is tested."
},
{
"nct": "NCT03718130",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': hantavirus disease (Hantaan and Puumala viruses). Open-label trial of HTNV DNA, PUUV DNA and their combination by electroporation; all six arms are experimental vaccine arms and none is a placebo or control. The 0.9% saline in the single-vaccine arms makes up the injection volume of a study vaccine; it is not a placebo given in place of one.",
"third_reader_reason": "Coder 1 built a comparison of PUUV DNA against saline on an HTNV background from the single-vaccine and combination arms; coder 2 excluded the trial. I excluded it: every arm gets a study DNA vaccine and the trial compares single vaccines with their combination, the saline is a volume filler in an experimental arm, and the pairing is arbitrary (HTNV on a PUUV background fits equally) and tests neither the titled combination against placebo (note 4)."
},
{
"nct": "NCT03738241",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get 2017 H7N9 vaccine with or without AS03; no placebo."
},
{
"nct": "NCT03760146",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC compared with 13vPnC (and 13vPnC/PPSV23); saline only fills the second slot in cohort 1."
},
{
"nct": "NCT03765073",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG020",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG012",
"EG021"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG013",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG015",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG017",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG014",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG022",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG019",
"EG023"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Women: Stage 1 nonpregnant and Stage 2-3 pregnant groups pooled (same design, saline control); infants of Stage 2-3 mothers as the offspring comparison. Left out Stage 1 booster groups EG003-EG005 (same participants, all boosted with GBS6, no placebo). GBS6 taken as a multivalent capsular polysaccharide (conjugate) vaccine; adjuvant by group, with or without AlPO4."
},
{
"nct": "NCT03769194",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03807245",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is buffer with Alhydrogel."
},
{
"nct": "NCT03807843",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V184 is a live measles (Schwarz) vector expressing chikungunya structural proteins, coded viral_vector."
},
{
"nct": "NCT03814590",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG011",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003",
"EG013"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A (18-40) and Part B (60-80) pooled, each with its own saline placebo. Plain groups unadjuvanted; AS01E/AS01B groups adjuvant other."
},
{
"nct": "NCT03819049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Cohort 2 has a placebo group; Cohort 1 (ExPEC10V doses, ExPEC4V, Prevnar 13) left out. ExPEC10V is an unadjuvanted O-antigen bioconjugate. Cohort 2 asked for a history of UTI, a past infection: patients false.",
"third_reader_reason": "The coders differed only in adjuvant (unknown or none). ExPEC10V, named by its maker's code VAC52416, is published like Janssen's other O-antigen bioconjugates as unadjuvanted, so none, as coder 2 had it."
},
{
"nct": "NCT03821272",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "PepCan (HPV16 E6 peptides with Candin) given to head and neck cancer patients in remission to reduce recurrence: a cancer/therapeutic vaccine."
},
{
"nct": "NCT03827395",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hepatitis_e"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEV 239 recombinant capsid protein on aluminium hydroxide; placebo normal saline."
},
{
"nct": "NCT03840174",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Seronegative and seropositive subgroups pooled. Platform other: V160 is a CMV vaccine whose platform the record does not describe (a whole-virus, replication-defective product); aluminium phosphate adjuvant stated."
},
{
"nct": "NCT03844386",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic MVA HIV vaccines in HIV-infected adults on ART."
},
{
"nct": "NCT03866187",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HBV vaccine regimen in chronic hepatitis B patients."
},
{
"nct": "NCT03869333",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Invaplex AR-DETOX: recombinant S. flexneri invasin proteins complexed with detoxified LPS, a subunit vaccine coded protein; adjuvant not stated. Placebo saline.",
"third_reader_reason": "The coders differed only in platform (protein or other). The product is a purified complex of invasin proteins with detoxified LPS, a subunit vaccine, and note 2 puts even outer-membrane vesicles under protein, so protein, as coder 1 had it."
},
{
"nct": "NCT03880474",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA vector carrying influenza NP+M1."
},
{
"nct": "NCT03883113",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Same participants reported by vaccination phase (EG000/EG001) and H3N2 challenge phase (EG002/EG003); took the vaccination-phase groups, which hold every vaccinated participant before the challenge virus that both arms got. Challenge-phase groups left out."
},
{
"nct": "NCT03916185",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three live-attenuated intranasal RSV candidates against one placebo (nose drops, composition not given)."
},
{
"nct": "NCT03917654",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pfs230D1M-EPA/AS01 compared with active control vaccines (Havrix, Typhim Vi, Menactra) and no-intervention arms; no placebo."
},
{
"nct": "NCT03918629",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "2-dose versus 3-dose C. difficile toxoid vaccine; placebo only replaces one dose in the 2-dose arm."
},
{
"nct": "NCT03926728",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG010",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: Chlamydia trachomatis (trachoma/genital chlamydia). CTH522 recombinant protein with CAF01 or CAF09b (liposomal adjuvants); some groups also got unadjuvanted CTH522 topical-ocular or intradermal boosts. Cohort F (F1, F2) saline placebo."
},
{
"nct": "NCT03934541",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MPER-656 peptide liposomes with aluminium hydroxide, in HIV-uninfected adults; two dose groups each with its own saline placebo, pooled."
},
{
"nct": "NCT03942406",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Boostrix (Tdap) prime with intranasal placebo on Day 1"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Boostrix-primed participants randomized to a BPZE1 or an intranasal placebo boost on Day 85 (EG002 vs EG003). BPZE1-primed groups (EG000, EG001) left out: both got BPZE1 at prime, and BPZE1 against Boostrix is an active control. Lead-in 10^7 groups (EG004-EG006) left out: no placebo-boost group of their own.",
"third_reader_reason": "The coders differed on eligibility. EG002 and EG003 got the same Boostrix prime and differ only in BPZE1 against intranasal placebo at the boost, which is a clean comparison on a shared background, as coder 1 took it; that every arm got some vaccine does not undo that pair."
},
{
"nct": "NCT03952650",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine on day 0 after each injection; artemether-lumefantrine clearance"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine on days 2 and 3 after each injection; artemether-lumefantrine clearance"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ-CVac: infectious sporozoites under antimalarial cover, live_attenuated. Main-phase three-dose groups only, split by the pyrimethamine schedule each vaccine group shares with its saline group. Single-dose pilot groups (EG000, EG002, EG004) have no placebo group; no chloroquine placebo group is reported.",
"third_reader_reason": "The coders differed in making one comparison or two; the background differs between the sets (pyrimethamine on day 0, or on days 2 and 3), so two, as coder 1 had it. Both coded the platform other, but note 2 makes live sporozoites given as the vaccine against malaria live_attenuated."
},
{
"nct": "NCT03961555",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests SYN023 monoclonal antibodies against human rabies immune globulin; every arm got rabies vaccine. Enrolled after WHO category 3 rabies exposure."
},
{
"nct": "NCT03964415",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.Mos4.HIV with clade C and mosaic gp140 protein, which the record calls adjuvanted and which is published as aluminium-phosphate adjuvanted. People at behavioural risk, not patients.",
"third_reader_reason": "The coders differed only in adjuvant (unknown or aluminium). The record calls the protein adjuvanted without naming it in the text shown, and the gp140 given with Ad26.Mos4.HIV is published as adjuvanted with aluminium phosphate, so aluminium, as coder 2 had it."
},
{
"nct": "NCT03969212",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Baloxavir marboxil (antiviral drug) given to influenza-infected index patients."
},
{
"nct": "NCT03970733",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Main study phase groups taken (first randomization). Booster-phase groups EG003/EG004 are a later re-randomization of higher-dose recipients and are left out."
},
{
"nct": "NCT03982199",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Main cohort groups (EG000, EG001). Revaccination subcohort groups EG002-EG013 left out: they report later periods in which placebo recipients got the vaccine, so the main groups are read as the period before each participant's revaccination. Ad26.RSV.preF with preF protein carries no adjuvant.",
"third_reader_reason": "The coders differed only in adjuvant (unknown or none). The Ad26.RSV.preF and RSV preF protein mixture is published as unadjuvanted, so none, as coder 2 had it."
},
{
"nct": "NCT03989102",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether/lumefantrine before 1st and 3rd injections"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform other: radiation-attenuated, non-replicating P. falciparum sporozoites (PfSPZ Vaccine). Women of childbearing potential, not pregnant."
},
{
"nct": "NCT03999554",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication intranasal influenza virus: live_attenuated. Sing2016 and Bris10 M2SR groups all against one saline placebo; Bris10 M2SR is a second study vaccine.",
"third_reader_reason": "The coders differed only in platform (other or live_attenuated). Note 2 names single-replication influenza virus as live_attenuated, as coder 2 had it."
},
{
"nct": "NCT03999996",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "TDV primary vaccination in parent trials"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Booster-phase groups taken: the parent trials' first randomization has no groups here, and the prior-to-booster groups are TDV recipients only."
},
{
"nct": "NCT04009824",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: mosquito-borne diseases; AGS-v PLUS is a synthetic mosquito salivary peptide vaccine. Adjuvants: none, Montanide ISA-51, Alhydrogel."
},
{
"nct": "NCT04019444",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd155-RG compared with RabAvert active control; placebo only fills dosing visits."
},
{
"nct": "NCT04026009",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "18-45 and 50-70 cohorts pooled. A subcohort of the 50-70 vaccine groups got a third dose at about Month 17 with no placebo counterpart; it is not reported separately, so the groups are kept."
},
{
"nct": "NCT04032093",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal groups and infant groups as separate comparisons; infants described by their mothers' vaccine."
},
{
"nct": "NCT04033068",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MV-ZIKA-RSP (V187), a measles-vectored Zika vaccine."
},
{
"nct": "NCT04060277",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "letermovir prophylaxis days 7-100 after haploidentical HCT"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Triplex (MVA carrying CMV antigens) given after transplant to prevent CMV infection, taken as preventive."
},
{
"nct": "NCT04064905",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT04071158",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "Tdap"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo group got Tdap, so only RSV+Tdap groups compare. RSV+placebo groups (EG000, EG002) left out: no placebo group without Tdap. Non-pregnant women."
},
{
"nct": "NCT04075318",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "UB-312 is an alpha-synuclein peptide vaccine for Parkinson's disease, a non-infectious target; Part B enrolled Parkinson's patients."
},
{
"nct": "NCT04078022",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Vaccine and Placebo Enrolled groups, which begin at vaccination and count each randomized participant once; the Challenged groups (EG002, EG003) are subsets after the challenge. SF2a-TT15 is a synthetic carbohydrate conjugated to tetanus toxoid; adjuvant not stated.",
"third_reader_reason": "The coders differed only in adjuvant (unknown or none). The record does not state it and a conjugate is not a platform that carries none, so unknown, as coder 1 had it."
},
{
"nct": "NCT04086472",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Clesrovimab is a monoclonal antibody, tested in an RSV challenge model."
},
{
"nct": "NCT04090658",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSVPreF3 with AS01B."
},
{
"nct": "NCT04091451",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shingrix (gE/AS01B) to prevent recurrence in adults with a prior zoster episode; prior episode taken as history, not a current condition, so patients false."
},
{
"nct": "NCT04126213",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Unadjuvanted RSVPreF3 maternal vaccine; mothers and their infants as separate comparisons."
},
{
"nct": "NCT04138056",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The groups run through the extension, in which every group, the dTpa + placebo group included, got an RSVPreF3 dose; no group covers the primary study alone. Non-pregnant women.",
"third_reader_reason": "The coders differed on eligibility. The only groups run past the point where the placebo recipients got the study vaccine, which note 7 makes ineligible; coder 1 decided so too but gave the reason other, where note 7 names groups_not_randomized_arms."
},
{
"nct": "NCT04152161",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BCG revaccination of adolescents against TB (its own target)."
},
{
"nct": "NCT04176133",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests entolimod (TLR5 agonist drug) on response to high-dose influenza vaccine that every arm received."
},
{
"nct": "NCT04228783",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Lot-consistency groups and booster cohort (with its own placebo series) pooled: Ad26.ZEBOV and MVA-BN-Filo are both viral vectors."
},
{
"nct": "NCT04232280",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CMV-seronegative and seropositive subgroups pooled."
},
{
"nct": "NCT04242264",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "oral S. sonnei 53G challenge on Day 57"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "EG002 got one WRSs2 dose after a placebo dose; all groups challenged."
},
{
"nct": "NCT04250363",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M5717 is an antimalarial drug tested in a PfSPZ challenge model; PfSPZ is the challenge agent, not a vaccine."
},
{
"nct": "NCT04305327",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Brodalumab and ustekinumab for psoriasis; no vaccine."
},
{
"nct": "NCT04318548",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets both MenB and MenACWY; placebo only staggers their timing."
},
{
"nct": "NCT04319380",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RTS,S/AS01 compared with seasonal chemoprevention arm given Td control vaccine; no vaccine placebo."
},
{
"nct": "NCT04333732",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "MMR (or MR) given to prevent COVID-19; both arms also got education and surveillance."
},
{
"nct": "NCT04348370",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "BCG Tice given to health care workers to prevent COVID-19."
},
{
"nct": "NCT04349553",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other",
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: paratyphoid A (ZH9PA, live attenuated S. Paratyphi A); ZH9 is live attenuated S. Typhi. Placebo saline in bicarbonate buffer, pooled across cohorts.",
"third_reader_reason": "The coders differed only in targets (typhoid with other, or typhoid alone). Two of the three vaccine groups got only ZH9PA, which is against paratyphoid A, a disease the list lacks, so typhoid and other, as coder 1 had it."
},
{
"nct": "NCT04355767",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Convalescent plasma for COVID-19 outpatients; no vaccine."
},
{
"nct": "NCT04365387",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"meningococcal",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests nemolizumab's effect on responses to Tdap and MCV4 that every arm received; atopic dermatitis patients."
},
{
"nct": "NCT04368728",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG013",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG008",
"EG009",
"EG012"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo-controlled follow-up groups for Phase 1 (BNT162b1 and BNT162b2), Phase 2/3 >=16 and Phase 3 12-15 pooled. Left out: open-label groups after placebo recipients crossed over (EG007, EG011, EG014); Phase 2 groups EG026/EG027, a subset of the Phase 2/3 >=16 participants; booster and BNT162b2SA groups (EG015-EG025), none with placebo."
},
{
"nct": "NCT04405076",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A groups only. Part B (open-label after unblinding, placebo recipients crossed over) and Part C (boosters, no placebo) left out."
},
{
"nct": "NCT04420221",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Dose-escalation epoch (healthy adults) and proof-of-principle epoch (adults with a recent S. aureus skin infection) pooled, each with its saline group. Platform other: Sa-5Ag, five S. aureus antigens the record does not describe. Adjuvant of the adjuvanted groups not named. A recent infection is a past infection: patients false.",
"third_reader_reason": "The coders differed in platform (other, or protein with polysaccharide), the adjuvanted groups' adjuvant (unknown or other) and patients. The record gives only five antigens and an unnamed adjuvant, and I am not confident enough of the candidate's published composition to go beyond it (note 1), so other and unknown as coder 1 had; by note 13 a past infection does not make patients true, as coder 2 had."
},
{
"nct": "NCT04424316",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "RSVpreF 120 mcg (Abrysvo, unadjuvanted); mothers and infants as separate comparisons."
},
{
"nct": "NCT04436276",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups run to about Day 808 and, by their descriptions, take in the Ad26.COV2.S dose placebo recipients were offered after unblinding and the ad hoc boosters; no group covers the blinded period alone.",
"third_reader_reason": "The coders differed on eligibility. The only groups run past the point where placebo recipients got the study vaccine, which note 7 makes ineligible; coder 1 decided so too but gave the reason other, where note 7 names groups_not_randomized_arms."
},
{
"nct": "NCT04440163",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY + saline compared with Trumenba + MenACWY-CRM, an active control; no placebo-only group."
},
{
"nct": "NCT04440176",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups get MenABCWY; they differ only in schedule (saline at month 12 in group 2)."
},
{
"nct": "NCT04445831",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tau-targeted vaccines for early Alzheimer's disease."
},
{
"nct": "NCT04449276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CVnCoV dose-escalation groups (2-20 ug) pooled against pooled placebo; placebo composition not given."
},
{
"nct": "NCT04453202",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG007",
"EG010"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF plus RSV preF protein, all three cohorts pooled; adjuvant not stated, taken as none (Janssen's Ad26/preF protein combination is unadjuvanted). Placebo 'matching', composition not given."
},
{
"nct": "NCT04470427",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Part A blinded groups; left out Part B open-label groups (incl. placebo crossovers) and the Part C booster."
},
{
"nct": "NCT04471038",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SAB-176 is an anti-influenza immunoglobulin, not a vaccine."
},
{
"nct": "NCT04473690",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "KBP-COVID-19 (plant-made subunit) with CpG adjuvant, low and high dose pooled; placebo buffered saline."
},
{
"nct": "NCT04475081",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "MMR-II given against COVID-19-associated sepsis (off target); placebo sterile saline, though the record lists the MMR intervention under both arms.",
"third_reader_reason": "The coders differed only in targets (covid19 or measles_mumps_rubella). By note 12 the target is the disease the trial gave the vaccine to prevent, COVID-19 and its sepsis, with off_target true, as coder 1 had it."
},
{
"nct": "NCT04491877",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG008"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live-attenuated RSVt, four cohorts and two formulations pooled; placebo composition not given."
},
{
"nct": "NCT04498247",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V591 (measles-vectored). Took the post-vaccination-1 groups, which count every participant once; left out the post-vaccination-2 groups (EG005-EG007), a subset of the same people."
},
{
"nct": "NCT04502693",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY lots compared with MenB and MenACWY schedules; placebo injections only keep the blind, no placebo-only group."
},
{
"nct": "NCT04505722",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the double-blind groups; left out the combined all-participants group (both arms) and the open-label booster groups."
},
{
"nct": "NCT04516746",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AZD1222 vs saline, double-blind period."
},
{
"nct": "NCT04520659",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the combined Groups 1 and 2 (EG004, EG005); EG000-EG003 report the same participants by group. Placebo nose drops, composition not given.",
"third_reader_reason": "The coders differed in which of the duplicate sets to take: the combined groups (coder 1) or Groups 1 and 2 apart (coder 2). Either counts each participant once over the same follow-up; I took the registrant's whole groups rather than their subsets, in line with note 6's preference for the group that spans the whole."
},
{
"nct": "NCT04523571",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT162b1 doses and both age cohorts pooled; placebo composition not given."
},
{
"nct": "NCT04523831",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Ivermectin plus doxycycline to treat COVID-19."
},
{
"nct": "NCT04526574",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups get 20vPnC and SIIV, coadministered or a month apart; groups span both vaccinations, so no placebo-controlled group."
},
{
"nct": "NCT04535453",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG007",
"EG009",
"EG011"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.COV2.S doses, intervals, adults and adolescents pooled against the four placebo groups. Placebo recipients were later offered active vaccine (Amendment 5 / unblinding); no separate post-crossover groups are reported, so the placebo groups may include some post-crossover time."
},
{
"nct": "NCT04537208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CoV2 preS dTM with AF03 or AS03 (both non-aluminium), plus an unadjuvanted high-dose group; both cohorts pooled; placebo 0.9% saline."
},
{
"nct": "NCT04542330",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "BCG-Denmark given to seniors for non-specific protection during the COVID-19 pandemic (off-target); placebo saline."
},
{
"nct": "NCT04544787",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo was given only among IPV-vaccinated participants, so took their groups (two novel OPV2 candidates vs placebo); OPV-vaccinated groups EG000-EG003 have no placebo group. Placebo sugar syrup with propylene glycol.",
"third_reader_reason": "The coders differed only in placebo content (inert or not_stated). The record gives the placebo as sugar syrup and propylene glycol, a sugar solution with an excipient and no antigen or adjuvant, so inert, as coder 1 had it."
},
{
"nct": "NCT04546724",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA1553 vs PBS."
},
{
"nct": "NCT04556981",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "M72/AS01E vs saline in virally suppressed people with HIV."
},
{
"nct": "NCT04568031",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AZD1222 vs saline, cohorts C and D as reported."
},
{
"nct": "NCT04569786",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V590 (rVSV-based) doses pooled across panels; placebo composition not given."
},
{
"nct": "NCT04588480",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the blinded groups; left out 'Placebo then BNT162b2' (post-crossover)."
},
{
"nct": "NCT04596878",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "GBS-NN/NN2 on Alhydrogel vs saline in pregnant women with and without HIV, strata pooled; no infant groups reported."
},
{
"nct": "NCT04605159",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Unadjuvanted RSV maternal vaccine; mothers one comparison, their infants a second. Placebo lyophilized sucrose in NaCl."
},
{
"nct": "NCT04606069",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Regadenoson to treat COVID-19."
},
{
"nct": "NCT04607408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CH505TF gp120 with GLA-SE vs saline in HIV-exposed uninfected newborns; placebo groups were reported pooled. Infants counted as healthy (exposed, not infected)."
},
{
"nct": "NCT04614948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Double-blind groups, including the non-FAS groups (randomized participants who had a COVID-19 vaccine outside the study beforehand); the combined all-participants group, which mixes arms and the open-label phase, left out.",
"third_reader_reason": "The coders differed in pooling the non-FAS groups with the main double-blind groups (coder 1) or making them a second comparison (coder 2). An earlier vaccination outside the study is a trait of a subgroup, not a background the trial gave, and the codebook pools subgroups of one design, so one comparison."
},
{
"nct": "NCT04626297",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests lebrikizumab's effect on vaccine responses; both arms get the same vaccines."
},
{
"nct": "NCT04634513",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG008"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Live attenuated S. flexneri 2a strain that also expresses ETEC antigens (a bacterial live vector); all cohorts pooled. Placebo sodium bicarbonate buffer."
},
{
"nct": "NCT04635423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups; left out the open-label extension groups. 9vHPV holds aluminium hydroxyphosphate sulfate; placebo 0.9% NaCl."
},
{
"nct": "NCT04642638",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "intradermal electroporation (CELLECTRA 2000)"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "INO-4800 with electroporation, Phase 2 and Phase 3 groups pooled; placebo saline sodium citrate buffer with the same electroporation."
},
{
"nct": "NCT04644484",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "SYN023 monoclonal antibodies vs HRIG for post-exposure prophylaxis; both arms get rabies vaccine."
},
{
"nct": "NCT04645966",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY compared with Trumenba or Bexsero plus Nimenrix; no placebo-only group."
},
{
"nct": "NCT04649151",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Part 1A blinded groups; left out Part 1B crossover, boosters, Part 2 and Part 3 open-label groups."
},
{
"nct": "NCT04650399",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA1553 vs PBS in adolescents."
},
{
"nct": "NCT04652102",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Phase 2b and 3 blinded groups as reported; participants censored at unblinding. Placebo composition not given."
},
{
"nct": "NCT04661579",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "RTS,S/AS01E controlled by rabies vaccine, an active control."
},
{
"nct": "NCT04668339",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Self-amplifying RNA ARCT-021. Took the first randomization's groups A-D (Day 1-207); left out the booster re-randomization groups (E1-H1) and the reactogenicity duplicates (EG008-EG015). Placebo saline."
},
{
"nct": "NCT04673149",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo only in the phase IIa part: Group 2b vs Group 2a. Phase I dose-escalation groups 1a-1c left out: no placebo group of their own.",
"third_reader_reason": "The coders differed on the phase I dose-escalation groups (EG000-EG002): left out by coder 1, pooled by coder 2. Placebo was randomized only in the phase IIa part, and note 17 leaves out cohorts with no placebo group of their own."
},
{
"nct": "NCT04674189",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CVnCoV two lots pooled vs placebo in health care workers; placebo composition not given."
},
{
"nct": "NCT04677660",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-919 is Takeda's mRNA-1273 (platform from the product, not the record); placebo composition not given."
},
{
"nct": "NCT04684914",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HepTcell is a therapeutic vaccine for chronic hepatitis B."
},
{
"nct": "NCT04707391",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY compared with MenACWY then MenB, an active control."
},
{
"nct": "NCT04712110",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-019 is Takeda's NVX-CoV2373 with Matrix-M (platform and adjuvant from the product, not the record); placebo composition not given."
},
{
"nct": "NCT04722003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "Target other: gonorrhoea. 4CMenB (recombinant proteins and outer-membrane vesicles with aluminium hydroxide) given to study protection against N. gonorrhoeae (off target); placebo saline.",
"third_reader_reason": "The coders differed only in targets (other or meningococcal). By note 12 the target is the disease the trial gave the vaccine to prevent, gonorrhoea, which the list lacks, so other with off_target true, as coder 1 had it."
},
{
"nct": "NCT04743011",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Nebulized heparin to treat COVID-19."
},
{
"nct": "NCT04754594",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG009"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal blinded groups (HIV-negative and HIV-positive pooled) one comparison, their infants a second; left out the 'placebo then BNT162b2' unblinded groups. Placebo composition not given."
},
{
"nct": "NCT04761822",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Every arm gets mRNA vaccine; placebo arms get one saline dose before the vaccine series, and their groups cover the whole study."
},
{
"nct": "NCT04766086",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "Tdap"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GBS6 + Tdap vs placebo + Tdap. Left out GBS6 + placebo (EG001), which has no placebo-alone group. GBS6 is a CPS-CRM197 conjugate; adjuvant not stated. Placebo saline."
},
{
"nct": "NCT04773665",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two eVLP vaccines (VBI-2902a, VBI-2905a, aluminium phosphate) in Phase 1a and 1b, pooled with both placebo groups; placebo 0.9% NaCl."
},
{
"nct": "NCT04785612",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Same participants reported in three periods; took vaccination until challenge (EG000, EG001), the groups that begin at vaccination and come before the RSV challenge both arms got. RSVpreF is unadjuvanted; placebo composition not given.",
"third_reader_reason": "The coders differed in which period's groups to take: vaccination until challenge (coder 1) or Day 28 to 155 after the challenge (coder 2). Note 6 takes the groups that begin at the first vaccination and, for a challenge trial, those before the challenge."
},
{
"nct": "NCT04785794",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed inactivated influenza vaccine at least 28 days later"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication intranasal influenza virus, coded live_attenuated (notes, 2). Both age cohorts pooled; each got its age's licensed inactivated influenza vaccine later in both arms. Placebo intranasal saline.",
"third_reader_reason": "The coders differed only in platform (live_attenuated vs other). The notes say a single-replication influenza virus given against influenza is live_attenuated, so I took coder 1's coding."
},
{
"nct": "NCT04789577",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H7N9 split-virion (Q-Pan) formulations with AS03A or AS03B pooled; placebo composition not given."
},
{
"nct": "NCT04796896",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG007",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part 2 randomized groups, three age cohorts pooled; left out Part 1 and Part 3 open-label groups, crossover groups and boosters."
},
{
"nct": "NCT04798027",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cohort 1 (one injection) and Cohort 2 (two injections) pooled. EG005 (medium dose) left out: that dose was given only in the sentinel cohort, which had no placebo group. EG003 and EG004 include sentinel participants the record pooled with the randomized cohort. Placebo 0.9% saline.",
"third_reader_reason": "The coders differed on EG005, the medium-dose group. That dose was given only in the sentinel cohort, which had no placebo group of its own, and the notes leave such cohorts out, so I left it out as coder 1 did."
},
{
"nct": "NCT04801420",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the randomized arms EG000-EG002 over the whole follow-up (the placebo arm got placebo in the booster phase too). EG003 and EG004 repeat the same participants. VLA15 is a recombinant OspA protein vaccine adjuvanted with aluminium hydroxide (product knowledge). Placebo PBS.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs aluminium). The record names VLA15, whose alum-adjuvanted formulation is published, and the notes say to use such knowledge, so I coded aluminium as coder 2 did."
},
{
"nct": "NCT04816643",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG012",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG020",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG023",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG013",
"EG017",
"EG021",
"EG024"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Phase 2/3 blinded D1-D2 groups of all three age cohorts and the 5-<12 troponin cohort (pooled), which count every randomized participant once. Left out: Phase 1 open-label groups (no placebo); blinded D3 groups (same participants again, and 5-<12 D3 and EG040 have no matching placebo); 12-<16 troponin groups (no placebo); open-label groups (placebo recipients crossed over). Placebo is 0.9% saline."
},
{
"nct": "NCT04817332",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Brensocatib, a DPP1 inhibitor, for severe COVID-19; no vaccine."
},
{
"nct": "NCT04826094",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All seven vaccine groups got Env-C DNA and gp145 protein with Rehydragel (aluminium hydroxide); some also ALF43 or dmLT. Pooled placebo arm got saline."
},
{
"nct": "NCT04830800",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "COVIVAC is NDV-HXP-S: an egg-grown, inactivated Newcastle disease virus displaying the SARS-CoV-2 spike, coded inactivated (a killed whole virus, not a live vector). EG003 holds CpG 1018; the other doses have no adjuvant. Placebo PBS.",
"third_reader_reason": "The coders differed only in platform (other vs inactivated). The record names COVIVAC, which is published as an inactivated Newcastle disease virus displaying spike, a killed whole virus, so I coded inactivated as coder 2 did."
},
{
"nct": "NCT04867174",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral messaging trial on COVID-19 vaccine take-up; no vaccine randomized."
},
{
"nct": "NCT04869982",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shingrix (RZV), AS01B adjuvant."
},
{
"nct": "NCT04875533",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC/saline vs 13vPnC/PPSV23, an active control."
},
{
"nct": "NCT04886154",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only the Phase I safety lead-in has placebo groups (saline). Phase II groups all got MenABCWY-2Gen or the Bexsero plus Menveo control and have no placebo group of their own, so they are left out. MenABCWY-2Gen joins MenB proteins and vesicles with ACWY conjugates; its adjuvant is not stated and I know no published composition for it (Bexsero's aluminium hydroxide makes aluminium likely).",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs aluminium, coder 2 moderately sure). The record doesn't state it and I know no published composition for this second-generation candidate, so by the notes' rule for knowledge short of confident I coded unknown, as coder 1 did."
},
{
"nct": "NCT04886596",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tables report the RSVPreF3 arm only as its two re-randomized subgroups (placebo or vaccine annually); together EG001+EG002 are the first-randomized vaccine arm, each participant once. Arexvy, AS01E adjuvant."
},
{
"nct": "NCT04887948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "BNT162b2 COVID-19 booster"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC plus BNT162b2 (EG000) against saline plus BNT162b2 (EG002). EG001 (20vPnC plus saline) could only pair with EG000 as a BNT162b2 comparison, which is left out (notes, 4). 20vPnC is a conjugate vaccine holding aluminium phosphate.",
"third_reader_reason": "The coders used EG000 in different comparisons: 20vPnC against saline with BNT162b2 in both (coder 1), or BNT162b2 against saline with 20vPnC in both (coder 2). The title names 20vPnC as the study vaccine and BNT162b2 as what it is given with, so by the notes I took the 20vPnC comparison, as coder 1 did."
},
{
"nct": "NCT04899336",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ExPEC9V (VAC52416) is an O-antigen bioconjugate given without adjuvant (product knowledge). Placebo 0.9% sodium chloride. patients false: the entry criterion is a history of urinary tract infection in the past 2 years, a past infection (notes, 13).",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none): the record names ExPEC9V and its maker's code, and the ExPEC bioconjugates are published as unadjuvanted, so none as coder 2 coded. I differ from both on patients: they coded true for the history of urinary tract infection, which the notes count as a past infection, so false."
},
{
"nct": "NCT04904549",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 (monovalent) and Stage 2 (bivalent) pooled, same design; crossover (EG004) and booster (EG005) groups left out. AS03 adjuvant."
},
{
"nct": "NCT04904744",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Outreach messaging trial; no vaccine randomized."
},
{
"nct": "NCT04908683",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF mixed with RSV preF protein in one injection; the vaccine has no adjuvant (product knowledge). Placebo called matching, composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none). The record names Ad26.RSV.preF with RSV preF protein, which is published as an unadjuvanted vaccine, so I coded none as coder 2 did."
},
{
"nct": "NCT04917861",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took main-study groups (Day 1-196, covering vaccination); extension-period groups EG004-EG007 are the same participants later and left out."
},
{
"nct": "NCT04940130",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before vaccination"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ Vaccine is radiation-attenuated, non-replicating whole sporozoites, coded live_attenuated (notes, 2); the record calls it non-adjuvanted. EG002 (enrolled, never assigned to an arm) left out. Placebo normal saline.",
"third_reader_reason": "The coders differed in platform (live_attenuated vs other). The notes say radiation-attenuated sporozoites are live_attenuated, so I took coder 1's coding, and its background, since both arms got artemether-lumefantrine before vaccination."
},
{
"nct": "NCT04951336",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Mushroom supplement tested for its effect on COVID-19 vaccination."
},
{
"nct": "NCT04955626",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Booster in people previously vaccinated with BNT162b2. Substudies A and B pooled (BNT162b2 30 mcg vs saline). Left out EG002 (placebo recipients after crossover) and substudies C-F (no placebo). EG000 includes the vaccine arm's open-label follow-up."
},
{
"nct": "NCT04956575",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Phase 1/2 groups only; Phase 2 NH and extension groups have an Afluria active comparator and no placebo."
},
{
"nct": "NCT04960397",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Four age/dose cohorts pooled. M2SR is single-replication (no progeny) but the record calls it live attenuated."
},
{
"nct": "NCT04969250",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Immediate vs deferred, one vs two doses; no placebo."
},
{
"nct": "NCT04973449",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AZD1222 and AZD2816 in every arm; no placebo."
},
{
"nct": "NCT04977479",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover with a 24-hour washout: every participant got the vaccine and the placebo a day apart. EG000 and EG001 are 3-hour windows after each product, not first-period arms, so the same participants are in both and half of each had the other product the day before. EG003 pools everyone; EG002 is an open-label booster. Enrolled for a systemic allergic reaction to a first dose.",
"third_reader_reason": "The coders differed on eligibility: coder 1 excluded the trial because its vaccine and placebo groups are by injection received; coder 2 took them as a comparison while unsure whether they hold the same people. With a 24-hour washout and groups that are 3-hour windows after each product, the groups are not first-period randomized arms, so I excluded it as coder 1 did."
},
{
"nct": "NCT04978454",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Influenza challenge virus vs sham inoculum; no vaccine."
},
{
"nct": "NCT04980391",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Mothers and infants as two comparisons. Unadjuvanted RSV MAT. High-risk pregnancies (patients true)."
},
{
"nct": "NCT04995081",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Mesenchymal stem cells for Parkinson's disease."
},
{
"nct": "NCT05007080",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets Ad26.COV2.S; dose levels and one vs two doses."
},
{
"nct": "NCT05012943",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Self-amplifying RNA. Took Day 1-92 groups of Phases 1-3b, before the Day 92 switchover; left out the Day 92-end groups (EG002 mixes arms) and Phase 3c (AstraZeneca active control)."
},
{
"nct": "NCT05027932",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intramuscular and intranasal groups pooled; each vaccine group got saline by the other route, and the placebo group saline by both. BPL-1357 is four BPL-inactivated whole avian influenza viruses with no adjuvant: the record lists nothing else in it, the same product is given into the nose, and product knowledge agrees.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none). The record gives BPL-1357's contents as four whole inactivated viruses, the same product is given intranasally, and it is known as an unadjuvanted whole-virus vaccine, so I coded none as coder 2 did."
},
{
"nct": "NCT05028361",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Simultaneous vs sequential COVID-19 mRNA and IIV4; both arms get both."
},
{
"nct": "NCT05045144",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Flu D-QIV influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV maternal vaccine plus Flu D-QIV (EG003) against placebo plus Flu D-QIV (EG004). The lot groups EG000-EG002 (RSV vaccine alone) have no placebo group of their own and are left out. GSK's RSV maternal vaccine (RSVPreF3 120 mcg) is unadjuvanted (product knowledge). The women were not pregnant. Placebo composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none). The record names GSK's RSV maternal vaccine, RSVPreF3 120 mcg, which is published as unadjuvanted, so I coded none as coder 2 did."
},
{
"nct": "NCT05062759",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tezepelumab tested for its effect on an influenza vaccine every arm receives."
},
{
"nct": "NCT05065619",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CoVLP (plant VLP) with AS03; the low-dose arm has no AE group."
},
{
"nct": "NCT05067933",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE tables report only vaccine groups; the Part 2 placebo arm has no AE group."
},
{
"nct": "NCT05069649",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ergoferon (oral drug) during SARS-CoV-2 vaccination."
},
{
"nct": "NCT05070546",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Three cohorts pooled (healthy 18-59, high-risk 18-59, 65 and older). patients true for the high-risk cohort, a randomized stratum enrolled for conditions that raise the risk of severe RSV disease. Ad26.RSV.preF with RSV preF protein has no adjuvant (product knowledge). Placebo called matching, composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none). The record names Ad26.RSV.preF with RSV preF protein, which is published as an unadjuvanted vaccine, so I coded none as coder 2 did."
},
{
"nct": "NCT05071313",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Fluzone High-Dose quadrivalent influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Day 1 groups (RSV vaccine plus high-dose influenza vaccine against placebo plus the same); the Day 29 groups EG002 and EG003 are the same participants after the control group got the RSV vaccine. Ad26.RSV.preF with RSV preF protein has no adjuvant (product knowledge). The influenza vaccine is the background, not a target. Placebo composition not given.",
"third_reader_reason": "The coders differed in adjuvant (unknown vs none) and in targets (rsv vs rsv and influenza). The vaccine is published as unadjuvanted, so none as coder 2 coded; the influenza vaccine went to both sides, so the target is RSV alone as coder 1 coded. I agree with neither in full."
},
{
"nct": "NCT05072080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three lots pooled; VLP on aluminium hydroxide; placebo is formulation buffer."
},
{
"nct": "NCT05073003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 adults only: the Stage 2 controls are licensed vaccines (Menveo, Boostrix, Typhim Vi, Infanrix hexa) with no placebo group. altSonflex1-2-3 is GVGH's GMMA vaccine, outer-membrane vesicles carrying the O-antigens, adsorbed on aluminium hydroxide (product knowledge); vesicles are coded protein (notes, 2). Placebo composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs aluminium): the product is published as adsorbed on aluminium hydroxide, so aluminium as coder 2 coded. Both gave platform other, but the vaccine is made of outer-membrane vesicles, which the notes code as protein, so I agree with neither in full."
},
{
"nct": "NCT05074303",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Beta-glucan supplement tested for its effect on an influenza vaccine every arm receives."
},
{
"nct": "NCT05074433",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Monoclonal antibodies (casirivimab+imdevimab) as pre-exposure prophylaxis."
},
{
"nct": "NCT05089630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pentamer/gB vaccine described as adjuvanted, adjuvant not named."
},
{
"nct": "NCT05091307",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo arms got Ad26.COV2.S on Day 29 and the AE groups cover Day 1 to end of study, so every group got the vaccine; no first-period groups."
},
{
"nct": "NCT05092646",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Amniotic fluid injection for ankle osteoarthritis."
},
{
"nct": "NCT05096208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three lots taken; pooled-lots group EG004 duplicates them and is left out. Abrysvo is unadjuvanted."
},
{
"nct": "NCT05099965",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Triplex was given to adults who already have cytomegalovirus (and HIV, on ART), to control an infection they carry, which the notes count as not preventive (10).",
"third_reader_reason": "The coders differed on eligibility: coder 2 took the vaccine as preventing complications of CMV, coder 1 as treating an existing infection. The notes say a cytomegalovirus vaccine given to people who already have the infection is not preventive, so I excluded it as coder 1 did."
},
{
"nct": "NCT05116241",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Boostrix Tdap"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1+Boostrix vs IN placebo+Boostrix. EG000 (BPZE1+IM placebo) has no matching placebo group; post-challenge substudy groups EG003-EG005 are subsets and left out."
},
{
"nct": "NCT05127434",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A (first randomization) taken; Part B revaccination groups EG002-EG003 left out."
},
{
"nct": "NCT05135273",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is rabies vaccine (Verorab), an active control."
},
{
"nct": "NCT05154578",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Mothers and infants as two comparisons; four schedules pooled."
},
{
"nct": "NCT05158140",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Concomitant vs nonconcomitant with mRNA-1273; every group gets V110 or V114 within the AE period."
},
{
"nct": "NCT05172544",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HydroVax-002 YFV is a hydrogen-peroxide-inactivated whole yellow fever virus formulated with aluminium hydroxide (product knowledge; the record doesn't state the adjuvant). Sentinel and expanded cohorts are pooled by dose in the tables. Placebo 0.9% saline.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs aluminium). The record names HydroVax-002 YFV, and the HydroVax inactivated vaccines are published as formulated with aluminium hydroxide, so I coded aluminium as coder 2 did."
},
{
"nct": "NCT05181657",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral COVID-19 education intervention."
},
{
"nct": "NCT05182125",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Parts A and B pooled, same background; Part B groups add CH505TF gp120 with GLA-SE."
},
{
"nct": "NCT05212168",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "norovirus GI.1 challenge inoculum about 29 days after vaccination"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral replication-defective Ad5 vector expressing norovirus VP1 with a dsRNA adjuvant vs matching placebo tablets; both arms then challenged with Norwalk virus. Groups are by vaccination actually received."
},
{
"nct": "NCT05212948",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover; AE groups span Day 1-435 and pool both periods, so no first-period groups are reported."
},
{
"nct": "NCT05216510",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SARS-CoV-2 peptide antigens given intradermally as a delayed-type hypersensitivity skin test (diagnostic), with Candin and diluent as within-subject controls; single-group, non-randomized cohorts by infection/vaccination history. Target listed is the disease the test concerns."
},
{
"nct": "NCT05219253",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shingrix (HZ/su), AS01B; placebo is lyophilised sucrose with saline."
},
{
"nct": "NCT05238025",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups as treated (a few misrandomized and multiple enrollers included). MVA carrying RSV antigens; placebo Tris-buffered saline."
},
{
"nct": "NCT05281094",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 is a bivalent norovirus virus-like particle vaccine adjuvanted with aluminium hydroxide (product knowledge). Placebo composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs aluminium). The record names HIL-214, published as a virus-like particle vaccine with aluminium hydroxide, so I coded aluminium as coder 2 did."
},
{
"nct": "NCT05289037",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get COVID-19 vaccines; no placebo."
},
{
"nct": "NCT05301322",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "seasonal inactivated influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Vaccination 1 groups (RSVpreF+SIIV vs placebo+SIIV); Vaccination 2 groups EG001, EG003 are the same participants after crossover. Abrysvo is unadjuvanted."
},
{
"nct": "NCT05310084",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal inactivated influenza vaccine"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the Visit 1 groups (BNT162b2+SIIV vs saline+SIIV). Visit 2 groups (EG001, EG003) left out: after the crossover."
},
{
"nct": "NCT05327816",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"protein",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The tables report Cohort 1 only, with one pooled placebo group. Ad26 RSV preF vectors with RSV preF proteins (EG003 proteins alone); the record lists each group's contents and names no adjuvant, and the Ad26.RSV.preF and preF protein vaccine they vary is unadjuvanted (product knowledge). Placebo composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none). The record lists each group's contents as vectors and proteins with no adjuvant, and the Ad26.RSV.preF and preF protein vaccine these formulations vary is published as unadjuvanted, so I coded none as coder 2 did."
},
{
"nct": "NCT05330975",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "Afluria Quadrivalent influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "mRNA-1273.214 COVID-19 vaccine; placebo at day 29 in both"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A: mRNA-1345+Afluria vs Afluria+placebo. Part B: mRNA-1345+mRNA-1273.214 vs mRNA-1273.214+placebo. Left out EG000 and EG003 (mRNA-1345+placebo, no placebo-only counterpart) and EG006 (open-label Part C revaccination)."
},
{
"nct": "NCT05349617",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLP vaccine on aluminium hydroxide; placebo is formulation buffer."
},
{
"nct": "NCT05370040",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups are Phase 1 saRNA dose cohorts only; the Phase 2 control arm was an EUA/licensed COVID-19 vaccine (active control), not reported in AE groups."
},
{
"nct": "NCT05375838",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "mRNA-1273 COVID-19 vaccine"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "No placebo-only group. mRNA-1010+mRNA-1273 (EG002) vs mRNA-1273+saline (EG000) differs only in mRNA-1010. EG002 could instead pair with EG001 (mRNA-1010+placebo) as an mRNA-1273 comparison; chose the investigational mRNA-1010. mRNA-1073 groups (EG003-EG005) and EG001 left out: no matching placebo group."
},
{
"nct": "NCT05393037",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V116 then placebo vs PCV15 then PPSV23: active control."
},
{
"nct": "NCT05397119",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "H5N1 inactivated influenza vaccine IM boost at month 6 in all arms"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal rH5 with nanoemulsion adjuvant (other) and rH5 without adjuvant (EG003, a vaccine group despite its placebo-comparator arm type) vs intranasal saline. Groups span the whole study including the common H5N1 IIV boost."
},
{
"nct": "NCT05422326",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets aH5N6c; Group 2 gets placebo only as its second dose. No placebo group."
},
{
"nct": "NCT05461131",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "B. pertussis challenge and azithromycin"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated pertussis vaccine BPZE1 vs placebo, both followed by challenge and azithromycin. Target is pertussis."
},
{
"nct": "NCT05480800",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other",
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other",
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other",
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 (Europe) only: iNTS-TCV conjugate, and iNTS-GMMA (outer membrane vesicles, platform other) plus TCV, vs placebo+saline. Stage 2 groups left out: control was MenACWY/Tdap/Vi (active). Other target: invasive nontyphoidal Salmonella. Adjuvant not stated."
},
{
"nct": "NCT05489770",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Black elderberry supplement in people with COVID-19; no vaccine."
},
{
"nct": "NCT05500417",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get CJCV2 (Campylobacter jejuni conjugate), with or without ALFQ; no placebo. Other target: Campylobacter."
},
{
"nct": "NCT05507450",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V181 (rDENVdelta30, live attenuated) three potencies vs placebo."
},
{
"nct": "NCT05512949",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label MVA-BN dose-sparing comparison; no placebo."
},
{
"nct": "NCT05526716",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Concomitant vs sequential V116 with QIV: both groups get V116 and QIV within the AE period, and the groups are not split at the day-30 crossover, so the placebo-controlled first period is not reported separately."
},
{
"nct": "NCT05559905",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Molnupiravir vs placebo in an RSV challenge model; no vaccine."
},
{
"nct": "NCT05581641",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT165b1 RNA malaria vaccine, three doses, vs matched placebo."
},
{
"nct": "NCT05584202",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE tables report only the two open-label Part 1 dose groups; no Part 2 randomized placebo group appears among the AE groups."
},
{
"nct": "NCT05590403",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Healthy and at-increased-risk strata of adults 50-59 pooled. EG004 (adults 60 and older, vaccine only) left out: no placebo group of its own. RSVPreF3 OA (Arexvy) is adjuvanted with AS01E. patients true: one randomized stratum was enrolled for chronic conditions that raise the risk of RSV disease (notes, 13). Placebo composition not given.",
"third_reader_reason": "The coders differed only on patients (true vs false). One of the trial's randomized strata was designed to enroll adults with chronic conditions that raise their risk of RSV disease, which the notes count as patients, so true as coder 1 coded."
},
{
"nct": "NCT05592223",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label BCG challenge model: every arm gets BCG; the arms test isoniazid or rifampin against no drug. No placebo."
},
{
"nct": "NCT05604209",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccines (ChAdOx1/MVA) in people with HIV on ART."
},
{
"nct": "NCT05604521",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ (radiation-attenuated whole sporozoites, non-replicating; coded live_attenuated as a weakened whole organism against itself, could be other) vs normal saline. Study terminated early; AEs to 28 days after dose 2, before the planned CHMI."
},
{
"nct": "NCT05626803",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral VXA bivalent norovirus tablets (adenovirus-vectored platform, from general knowledge; record gives IU/dose only). EG002 left out: open-label sentinels, not randomized."
},
{
"nct": "NCT05630859",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Phase 1 and Phase 2 groups. NgG is a GMMA (outer membrane vesicle) vaccine, platform other; adjuvant not stated. Other target: gonorrhoea."
},
{
"nct": "NCT05634811",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Overall groups (EG004, EG005); the age-band groups EG000-EG003 are the same participants. VLA15 (OspA) aluminium hydroxide adjuvant from general knowledge, not stated in record. Includes the month-18 booster or placebo."
},
{
"nct": "NCT05639894",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG019",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006",
"EG013",
"EG020"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 sentinel and main cohorts (18-50) and Stage 2 (60 and older) pooled from the first vaccination, each with its own placebo group. Booster cohort groups EG014-EG017 left out: a later re-randomization of main cohort participants already counted. The candidate is encapsulated in lipid nanoparticles and supplied frozen, which is an RNA vaccine (the sponsor's RSV mRNA candidate); mRNA carries no adjuvant. Placebo called matched, composition not given.",
"third_reader_reason": "The coders differed in platform and adjuvant (other and unknown vs mrna and none). The record describes a candidate encapsulated in a lipid nanoparticle formulation, which is how RNA vaccines are made and what this sponsor's RSV candidate is known to be, so I coded mrna and none as coder 2 did."
},
{
"nct": "NCT05654441",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flulaval (split inactivated, unadjuvanted) vs saline, used as a low-grade inflammatory challenge in a social-behavior study; AEs over about 30 hours."
},
{
"nct": "NCT05687279",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSVt vs placebo in infants. The record describes the placebo's form as a suspension of virus, apparently copied from the vaccine; composition treated as not stated. Placebo recipients were contacts of vaccinees in a transmissibility design."
},
{
"nct": "NCT05696080",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V116 then placebo vs PCV15 then PPSV23: active control."
},
{
"nct": "NCT05762393",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rSm-p80 with GLA-SE adjuvant vs saline. Other target: schistosomiasis."
},
{
"nct": "NCT05770895",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HBV arenavirus-vector vaccines (healthy volunteers in Phase 1a, chronic hepatitis B in Phase 1b)."
},
{
"nct": "NCT05782179",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled healthy older and obese/diabetic older cohorts. patients true because one cohort was enrolled for obesity or diabetes."
},
{
"nct": "NCT05788237",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza",
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SSA: combination RSVpreF+qIRV then placebo vs qIRV then RSVpreF; no placebo in place of RSVpreF at Visit 1, and the Visit 2 placebo group had already got RSVpreF. SSB compares two formulations."
},
{
"nct": "NCT05818124",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Molnupiravir and oseltamivir in an influenza challenge model; no vaccine."
},
{
"nct": "NCT05836012",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant vaccines"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 is the bivalent GI.1/GII.4 norovirus VLP vaccine (as NCT06007781's record says); its aluminium hydroxide (with MPL) adjuvant is from general knowledge, not stated here."
},
{
"nct": "NCT05842967",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Substudy A only (adults 18-59 at high risk of severe RSV disease). Substudy B groups EG002 and EG003 left out: open label, no placebo. RSVpreF (Abrysvo) is unadjuvanted. The placebo is a lyophile matched to RSVpreF, with no composition given.",
"third_reader_reason": "The coders differed only in placebo content (not_stated vs inert). The record calls the placebo a lyophile matched to RSVpreF and gives no composition, which the notes code as not_stated, so I took coder 1's coding."
},
{
"nct": "NCT05886777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed quadrivalent influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "RSVpreF and bivalent BNT162b2 coadministered"
}
],
"targets": [
"covid19",
"influenza",
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "1: the combination of RSVpreF and BNT162b2 with QIV (EG000) against saline with QIV (EG004), the comparison that tests the study vaccine; EG000 against EG001 would be a QIV comparison and is left out (notes, 4). 2: QIV against saline, both with RSVpreF and BNT162b2 coadministered (EG006 against EG005), a licensed vaccine against placebo (notes, 9). The licensed QIV is not named, so its platform is other (split virus would be inactivated, surface antigen or recombinant would be protein) and its adjuvant unknown. EG001, EG002 and EG003 have no matching placebo group.",
"third_reader_reason": "The coders differed on how to use EG000: against EG004 as a test of the combination vaccine with QIV in both (coder 1), or against EG001 as a test of QIV (coder 2); and on the platform of the unnamed QIV (other vs inactivated). The title names the combined RSV and COVID-19 vaccine as the study vaccine, so by the notes EG000 serves in its comparison, and an unnamed licensed QIV could be split virus or surface antigen, so other: coder 1's coding throughout."
},
{
"nct": "NCT05891236",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MAM01 is a monoclonal antibody against malaria, with CHMI; no vaccine."
},
{
"nct": "NCT05899816",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Rocatinlimab vs placebo for its effect on vaccine antibody responses in atopic dermatitis; the vaccines are not arms of the trial."
},
{
"nct": "NCT05901636",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Influenza G1 mHA with and without Al(OH)3, one or two doses, vs pooled placebo."
},
{
"nct": "NCT05903183",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other",
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the main trial part groups; the observational extension groups (EG003, EG004) are a subset of the same participants. IVX-A12 is an RSV/hMPV VLP vaccine, with MF59 in EG001; placebo is diluent. Other target: human metapneumovirus."
},
{
"nct": "NCT05940194",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "COVIVAC vs AZD1222: active control."
},
{
"nct": "NCT05972993",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG008"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Part A and Part B mRNA-CR-04 doses vs their placebo groups."
},
{
"nct": "NCT05975099",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "mRNA-1975 and mRNA-1982 dose levels vs vaccine-matching placebo."
},
{
"nct": "NCT06007781",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 norovirus GI.1/GII.4 VLP vs placebo; aluminium hydroxide (with MPL) adjuvant from general knowledge, not stated in record."
},
{
"nct": "NCT06022224",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the overall groups EG000, EG001; EG002-EG015 repeat the same participants by AE category."
},
{
"nct": "NCT06057064",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AZD3152 is a monoclonal antibody for COVID-19 pre-exposure prophylaxis."
},
{
"nct": "NCT06060067",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-003 vs saline, pooled adult and child cohorts."
},
{
"nct": "NCT06060457",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Coadministered vs sequential mRNA-1345 with Fluzone HD: both groups get mRNA-1345 and Fluzone HD within the AE period, and the groups are not split at the day-22 crossover."
},
{
"nct": "NCT06069544",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG010",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT165c/BNT165d RNA vaccines, pooled across doses and both schedules, vs saline. Title mentions CHMI, not described in the arms."
},
{
"nct": "NCT06097273",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "mRNA-1083 plus placebo vs licensed influenza plus COVID-19 vaccines: active control."
},
{
"nct": "NCT06097299",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Took Part A Cohort 1 (2 to <5 years). Cohort 2 groups (EG004-EG006) left out: no placebo. Part B groups (EG007-EG010) left out: re-enrolled subset of Cohort 1, already counted."
},
{
"nct": "NCT06134804",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "high-dose quadrivalent influenza vaccine"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the post-dose 1 groups (Day 1 to Day 30): ExPEC9V with high-dose influenza vaccine against placebo with the same. The post-dose 2 groups are the same participants after the control group got ExPEC9V. ExPEC9V (VAC52416) is an O-antigen bioconjugate given without adjuvant (product knowledge). Placebo called matching, composition not given.",
"third_reader_reason": "The coders differed only in adjuvant (unknown vs none). The record names ExPEC9V and its maker's code, and the ExPEC bioconjugates are published as unadjuvanted, so I coded none as coder 2 did."
},
{
"nct": "NCT06178991",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Combination vaccines plus placebo vs licensed COVID-19 plus influenza vaccines, and Cohort 3 vs single vaccines: active controls only."
},
{
"nct": "NCT06237049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed recombinant influenza vaccine (RIV)"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT162b2 plus RIV (EG001) against saline plus RIV (EG003). EG001 could pair with EG002 as an RIV comparison instead; the titles name the modified RNA COVID-19 vaccine first and it is the sponsor's study product, so I took its comparison (notes, 4). EG000 (the combination plus saline) has no group with saline in place of the combination, and EG002 is left out with the RIV comparison.",
"third_reader_reason": "The coders used EG001 in different comparisons: BNT162b2 against saline with RIV in both (coder 1), or RIV against saline with BNT162b2 in both (coder 2, who still listed both platforms). The titles name both vaccines, the modified RNA COVID-19 vaccine first and as the study product, with RIV its licensed partner, so by the notes I took the BNT162b2 comparison, as coder 1 did."
},
{
"nct": "NCT06279871",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets ARCT-2303 and an influenza vaccine, coadministered or 28 days apart, and the groups span both doses, so the placebo-controlled first period is not reported separately."
},
{
"nct": "NCT06325657",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Pregnant women living with HIV (maternal groups) and their infants (the offspring comparison). RSVpreF (Abrysvo) is unadjuvanted. The placebo is described as matching RSVpreF without active vaccine, with no composition given.",
"third_reader_reason": "The coders differed only in placebo content (not_stated vs inert). The record says the placebo matches RSVpreF without the active vaccine and gives no composition, which the notes code as not_stated, so I took coder 1's coding."
},
{
"nct": "NCT06461026",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "L9LS is a monoclonal antibody vs saline; every infant later gets R21/Matrix-M, reported as one group (EG006)."
},
{
"nct": "NCT06546423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated B/HPIV3 vectors carrying HMPV F (listed as both platforms: a live HPIV3 vaccine and a vector for HMPV) vs Lactated Ringer's, the vaccine's diluent. Other targets: human metapneumovirus and parainfluenza 3."
},
{
"nct": "NCT06551181",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the China cohort only (vaccine EG001 vs saline placebo EG002). Left out EG000, the overseas cohort, which got vaccine with no placebo arm of its own and a different follow-up. RSVPreF3 OA is adjuvanted with AS01E."
},
{
"nct": "NCT06593587",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSVpreF 120 mcg (prefusion F subunit, unadjuvanted) vs placebo of unstated composition."
},
{
"nct": "NCT06602531",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control groups (EG003, EG007) got a licensed influenza vaccine at dose 1 and saline only at dose 2, so they are active controls for the self-amplifying mRNA pandemic influenza vaccine; no group got placebo in place of every vaccine dose."
},
{
"nct": "NCT06614725",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both cohorts pooled (60 and older; 50-59 at increased risk of RSV disease). RSVPreF3 OA is adjuvanted with AS01E. Placebo saline. patients true: the 50-59 stratum was enrolled for conditions that raise the risk of RSV disease (notes, 13).",
"third_reader_reason": "The coders differed only on patients (true vs false). The 50-59 stratum was designed to enroll adults with conditions that raise their risk of RSV disease, and the notes make patients true when one randomized stratum is so designed, so true as coder 1 coded."
},
{
"nct": "NCT06634797",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the first-period groups (Day 1 injection: mRNA-1273.712 EG000 vs sodium chloride placebo EG002). Left out EG001 and EG003, the Day 29 groups after crossover."
},
{
"nct": "NCT06683352",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got a COVID-19 vaccine, an investigational influenza vaccine, or both (or licensed influenza plus COVID-19 vaccines); the saline is a second blinding injection, never given in place of all vaccine. The trial compares vaccines and doses."
},
{
"nct": "NCT06705140",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal RSVt (live-attenuated RSV) at low, standard and high doses; pooled cohort 1 (born preterm) and cohort 2 (full-term) into one comparison. Tables report only SD and placebo for cohort 1 (its HD and second control arms have no groups). Preterm-born toddlers aged 6-21 months, listed as healthy volunteers, so patients false."
},
{
"nct": "NCT06831812",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AV-1959R is a beta-amyloid vaccine against Alzheimer's disease, a non-infectious target; its placebo is adjuvant alone."
},
{
"nct": "NCT07254728",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral tablet bivalent norovirus vaccine dosed in infectious units (Vaxart's oral adenovirus-vectored platform), so viral_vector; no adjuvant stated, so none by the platform rule, though this platform's vector is reported to express a dsRNA adjuvant. Mothers were lactating, not pregnant; their breast-fed infants (no direct intervention) are taken as an offspring comparison by analogy with the pregnancy rule."
}
]